Advocate Aurora Health

Advocate Aurora Health Institutional Repository
Aurora Health Care Books, Documents, and
Pamphlets

Aurora Health Care

March 2017

Aurora Health Care Metro Region Cancer Programs Annual
Report, 1998
Aurora Health Care

Follow this and additional works at: https://institutionalrepository.aah.org/ahc_books
This Document is brought to you for free and open access by the Aurora Health Care at Advocate Aurora Health
Institutional Repository. It has been accepted for inclusion in Aurora Health Care Books, Documents, and
Pamphlets by an authorized administrator of Advocate Aurora Health Institutional Repository. For more
information, please contact AAH-Library@aah.org.

Ziebert Medical Library
‘est Allis Memorial Hospital
g9o1 West Lincoln Avenue
Nest Allis, WI 53227-0901
CDc,

co—

Aurora Health Care

Metro

Region

Cancer
Programs

Annual Report

Special Focus

Breast Cancer

__..•__,•‘

‘.

w

‘‘

BREAST CANCER

4

7-

4
4

WAME

QZ
201
C215ar
1998

St. Luke’s Medical Center
Sinai Samaritan Medical Center
West Allis Memorial Hospital

0

1997
Data Review

AuroraRe aith C are®

C
CD

rTh
C
CD

he postage stamp illustrated on
the cover of this annual report is the first
“semipostal” stamp ever issued in the
United States. The cost of the stamp, 40
cents, includes a surcharge to be donated
to breast cancer research.
The idea for the stamp came from
Dr. Balasz Bodal, a surgeon in
Sacramento, California, who envisioned
raising funds for cancer research by
charging an extra penny for each first
class postage stamp. With the help of
Congressman Vic Fazio and Senator
Dianne Feinstein of California, a bill
permitting the U.S. Postal Service to issue
semipostal stamps was introduced in
Congress, overwhelmingly passed, and
signed into law by President Bill Clinton
in August 1997.

The stamp was officially issued on
July 29, 199$ in ceremonies at the
White House. The Milwaukee Post
Office held the unveiling ceremony
for the stamp the same day in the
Vince Lombardi Cancer Clinic at
St. Luke’s Medical Center.
The self-adhesive stamp has been
printed in a quantity of 200 million.
If all the stamps are sold, breast cancer
research will receive $1$ million (less
printing, distribution and publicity costs).
From the article “Breast Cancer Research
Stamp Issued” by April G. Fritz, ART,
CTR. The article first appeared in the
August 1998 issue of Journal of Registry
Management and is excerpted here with
tt’
permission.

d
n.
c
w

Milwaukee
3ffice held the
‘ig ceremony for
ist cancer stamp
7ince Lombardi
ncer Clinic.

5l

in
g(
bi
TI
b€
h
re
se

L
WAMH QZ 201 C215ar
1998

Cancer programs annual
report

About Our Cover “Research Stamp”

Inside Front Cover

Metro Region Cancer Services Report

2

-4

Cancer Committee Chairpersons Reports

St. Luke’s Medical Center

3

Sinai Samaritan Medical Center

4 5

West Allis Memorial Hospital

6

-

Breast Cancer Experience and Excellence

Overview

7

Five-Year Comparison of Metro Region Statistics

8

Metro Region Breast Health Task Force

11

Breast Conservation Surgery for Breast Cancer

12

Progress with Male Breast Cancer

14

Radiation Therapy in Primary Breast Cancer

16

Breast Cancer in America’s Racial & Ethnic Minorities

19

Sentinel Lymph Node Study

21

Autologous Bone Marrow Transplant

23

Genetic Susceptibility Testing for Breast and Ovarian Cancer

26 29

Pathology and Prognostic Markers in Breast Cancer

30

Wisconsin Women s Cancer Control Program

34

35

Bieast Cance; Related Research

36

39

-

10

4
-

-

-

-

-

-

13
15
18
22

25

-

-

-

33

Regional Activities in Aurora’s Metro Region

Other Research

40 41

Support Groups

42 44

Special Events

45

Cancer Conferences

46

Registry Report

47

1997 Statistical Summary Review

48

Cancer Services Directory

54 55

Cancer Committee Members 1997

56 57

-

-

-

53

-

1

1

20

-

-‘

C

1•

ince the summer of 1997,
Aurora Health Care’s administrative team
has challenged itself to evaluate, explore
and plan how the system should be
organized to meet present and future
challenges. The first on the list of tasks
was the development of a new
organizational structure. This new
regional structure was built on furthering
the development of a system to provide
integrated care to support care
management, with the overall goal to
have a well coordinated seamless system
of care that is high quality and cost
effective to benefit our patients.
This corporate strategy is especially
critical to cancer care in order to
support our excellent programs and to
compete effectively in today’s managed
care environment. Costs associated with
cancer care currently consume 20% of
the U.S. health care dollar and are
projected to consume 25% of that same
dollar by the year 2010. Capitation and
“carve out” contracts are already
occurring in the cancer care market.
There is also a threat to cancer-related
research programs due to lack of
reimbursement for “experimental” or
“investigational” treatment and off-label
drug usage. This also poses a real threat
to patients under treatment.

Other health care systems across the
country have or are developing cancer
care networks and alliances that will
compete in their local, regional and
national market places. The success of
health care reform will be in large part
dependent upon the stewardship of
cancer care providers. In essence, the
challenge will be to provide care for
an increasing number of patients,
further enhance quality, and reduce
costs per case.
In preparation to meet these challenges,
the Cancer Services Teams at St. Luke’s
Medical Center, West Allis Memorial
Hospital and Sinai Samaritan Medical
Center have begun to come together
to discuss: unique disease-specific
approaches to patient care coordination;
a regional plan to demonstrate quality;
the development of a research agenda
that will keep Aurora on the forefront of
knowledge in cancer; a plan to educate
and market proven cost effective
prevention and early detection techniques
to primary care providers; and the
promotion of community-based
education and outreach awareness of
Aurora cancer care sites as the source for
personalized advanced cancer diagnosis
and treatment.
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Marija Bjegovich-Weidman, RN, MSN
Regional Director, Cancer & HW Services
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s chairperson of the Cancer
Committee at St. Luke’s Medical Center
for almost ten years, and of the Division
of Radiation Oncology for even longer,
I find myself in a reflective mood,
especially since by the time this report is
published, I will have moved on to the
next stage of my life retirement. I am
grateful to have been present during this
exciting time of rapid growth and
development of the oncology program
at St. Luke’s Medical Center, and am
proud that we are now the preeminent
program in the city.

As we look back on the year’s activities
of the Cancer Program and Committee,
many accomplishments stand out. Some
of the highlights of 1997 include:
Initiation of the radiosurgery program,
a joint project of neurosurgery and
radiation oncology.
Initiation of sentinel lymph node
mapping and ABBI excisions for
breast cancers.
Regionalization of the cancer program
in the Aurora Metro Region.

—

—

—

—

Educational efforts continued as usual,
with four grand rounds focusing on
cancer, plus one Schroeder Fellows
Program. Research efforts included the
usual cooperative group studies and new
protocols in areas of St. Luke’s expertise
of immunotherapy and autologous bone
marrow transplant. Many community
outreach efforts also took place. Many
of the activities coordinated with the
committee’s goals in the areas of
research, community outreach and
care evaluation.

I am also pleased that this report is on
breast cancer, the most common cancer
in American women but fortunately no
longer the most frequent cause of death
from cancer in the same population.
Today the chances for cure are improving
for women with this disease. Better
methods are available for early
detection. More options that are less
traumatic are available for primary
treatment. And information is being
gleaned at the level of the cell that helps
us to understand the nature of this
disease as documented in this, our first
Aurora Metro Region report.

And so with this final line, I thank
my fellow physicians and St. Luke’s
Medical Center, its patients and staff,
for providing me with many challenging
and interesting years. And to those who
follow, especially Jeff Derus, MD, the
new chair of the Cancer Committee,
may you enjoy the same satisfaction
through your efforts and involvement to
improve the lives of cancer patients in
our community.

Breast cancer is very important to me for
both professional and personal reasons.
Not only have I participated as a
professional advocate for women in
treatment options for early breast cancer,
but on the home front, I saw the changes
benefit several aunts long after my
mother was treated, when I was a
teenager, with a radical mastectomy and
no adjuvant systemic treatment for a
small breast cancer with spread to nodes.
She was lucky. She lived to age 82, and
died of other causes.

St. Luke’s &eJical Center
Marcia J.S. Richards, MD
Chairperson, Cancer Committee
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n behalf of Sinai Samaritan
Medical Center, I am pleased to
contribute our cancer statistics and
cancer program report to this
publication, the first combined Aurora
Metro Region Cancer Program Report.
This collaboration reflects a closer
integration of Aurora Health Care cancer
activities in the Milwaukee metropolitan
area. Closer integration of our registries,
tumor conferences and cancer-related
services, while building upon the unique
capabilities of each institution, should
result in greater efficiency, reduced
duplication and dependable quality for
the public.
Evidence of quality at Sinai Samaritan
Medical Center was the four-year
approval it received during 1997 by
the American College of Surgeons’
Commission on Cancer (COC).
A four-year approval demonstrates
that all mandatory standards were
met or exceeded. All staff are to be
congratulated on achieving this highest
award for compliance. The COC
particularly commended Sinai Samaritan
Medical Center for its tumor board and
clinical trials participation. Clinical trials
are an important part of the research
performed at Sinai Samaritan Medical
Center. The clinical trials programs
include the Eastern Cooperative
Oncology Group (ECOG), the Radiation
Therapy Oncology Group (RTOG), and
the National Surgical Adjuvant Breast
and Bowel Project (NSABP). Noteworthy
was that our institution was Milwaukee

headquarters for the NSABP National
Breast Cancer Prevention Trial using the
drug tamoxifen which made headline
news in early 1998. This trial demon
strated for the first time that breast
cancers can be prevented in high risk
women.
We are particularly proud of our
outreach programs, some of which
are implemented through partnership
with the Wisconsin Division of the
American Cancer Society. Sinai Samaritan
Medical Center helps to support the
annual Southeastern Wisconsin Cancer
Conference. This is an annual
educational conference that brings
national speakers to Wisconsin and
which is free to health care providers in
this area. Among our many education
projects are the Cancer Education
Support Group, the Tempkin Foundation
Funding for skin cancer programs, and
the Breast Health Center with its
outreach particularly to minority groups.
The hospital conducts smoking cessation
groups, community work groups through
local churches, and breast self
examinations classes. We participated in
the “Faces of Breast Cancer,” a program
sponsored by the National Breast Cancer
Coalition in June 1997. Physicians at
Sinai Samaritan Medical Center provide
care for individuals screened through the
Milwaukee Breast Cancer Awareness
Project, the mobile unit that makes free
mammograms and breast examinations
available to the public. These activities
require dedicated physicians, nurses,

Sinai Samaritan &edical Center
William L. Donegan, MD
Chairman, Cancer Committee

they are eating healthier diets with less
fat and more fruits and cruciferous
vegetables. Prevention is becoming a
major effort, and screening, particularly
with mammography, is detecting cancers
when they are earlier and more curable.
Treatment in general is becoming more
effective and better tolerated. The
challenge is to keep those incidence
and mortality rates going down. I
congratulate the Cancer Committee and
all of the individuals at Sinai Samaritan
Medical Center who are dedicated to
doing so.

administrators and support staff, all of
whom are aware that cancer places a
major health burden on the public and
make that extra effort to reduce it. This
army of individuals is turning things
around. They provide the helping hands
that touch, serve and reach out.
The latest national data show that
age-adjusted death rates and incidence
rates from cancer in the United States
have declined five percent since 1990,
and the trend seems to be continuing.
Here is solid evidence that our work
is beginning to pay off. The public is
becoming increasingly aware that much
of the cancer problem is self-inflicted.
Fewer Americans are smoking, and

t:
Sinai Samaritan
Medical Center
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Management guideline recommendations
for treatment of patients with breast
cancer were presented to Dr. David
Farrell, Chief of Surgery. Diagnostic and
breast conservation procedures, new
biopsy techniques, and the use of sentinel
lymph node imaging for diagnostic and
staging procedures will be implemented
in the future. A collaboration with
St. Luke’s Medical Center on National
Cancer Survivors Day was very
successful. We look forward to joining
Special thanks is extended to Priscilla
forces with the other Aurora facilities for
Eckert and Sharon Miller, Clinical Data
e projects. A Tumor Board
Registrars, for their efforts in formulating futur
satisfaction survey indicated that our
an excellent Cancer Registry and helping
Friday noon meetings are very well
to make the Cancer Program what it is
received.
today. Priscilla will be greatly missed
of
years
13
after recently retiring after
We welcome Dr. Kenneth Bastin and
service to West Allis Memorial Hospital.
Dr. Rakesh Jagetia and express our
I am pleased to report that David
appreciation to them for orchestrating a
VanWinkle, CTR, has transferred from
very cohesive transition of radiation
St. Luke’s Hospital to assume Priscilla’s
therapy care for our patients.
position as Clinical Data Registrar.
He has many years of experience and
As chairman of the Cancer Committee at
will be an asset to the registry.
West Allis Memorial Hospital, I look
forward to a cooperative effort among
Patient education and awareness were
the hospital staff, the patients, their
focused in the implementation of several
families and the community in providing
new programs at West Allis Memorial
the best cancer care and information we
Hospital this year. Expansion of the
can offer.
library as a resource to include Internet
been
has
s
topic
access for cancer-related
very successful. Information about area
hospice programs, including referral
requirements and availability, was
prepared by an ad hoc committee and
provided to patients and family members.

am pleased to report that the
Cancer Program of West Allis Memorial
Hospital received the highest approval
evaluation from the American College of
Surgeons through the year 2002.
Everyone involved in the agenda and
implementation of our programs is
commended for a job well done. To
receive the highest grade in all areas of
review is a tremendous accomplishment.

‘A4t

A118 &emoria1 }Tospital

Maury Berger, MD

Chairman, Cancer Committee
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C.?
his year’s in-depth site study is
dedicated to breast cancer. The articles were
written by our physicians and staff and are
reflective of the excellent services provided
to breast cancer patients throughout Aurora
Health Care. Our patient care philosophy
revolves around prevention, early detection,
comprehensive diagnostic and treatment
services and a support system that offers
the most comprehensive network of
professionals in Southeastern Wisconsin.

The comprehensive breast care programs
at St. Luke’s Medical Center and Sinai
Samaritan Medical Center provide a warm
and personal atmosphere in which breast
care coordinators work closely with
patients and their physicians to plan
individualized care. Both programs offer a
wide range of services, including education,
screening, diagnosis and treatment. The
Breast Care Programs assure that a woman
is treated as a complete person, addressing
emotional, spiritual, psychological and
physical needs.

In 1997 alone, 464 cases of breast cancer
were diagnosed and/or treated in the
hospitals of the Aurora Metro Region,
which reflects the fact that patients choose
our hospitals and physicians as a resource
for cost effective, high quality, personalized
oncology care. As the home of the Vince
Lombardi Cancer Clinic, we share Coach
Lombardi’s “Commitment to Excellence”
in patient care, patient education and
cancer research.

To stay on the cutting edge of breast
cancer treatment, Breast Cancer
Conferences are held on a regular basis.
These conferences give experts a forum
to discuss and consult with each other on
breast cancer cases. This multidisciplinary
approach helps design the best treatment
plans for our patients.
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A Five-Year Comparison 0f Breast Cancer Statistics
Aurora Metro Region Hospitals 1 993- 1 997

CD
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ith the advent of
screening mammography and increased
education about breast self examination,
a greater number of patients within
Aurora Health Care and across the nation
have their cancers detected at an earlier
stage. Breast cancer is no longer a disease
that is treated exclusively with surgery.
Now, a multidisciplinary team of

physicians coordinates an array of
treatment modalities to eradicate the
disease in the best way possible.
The statistics on the following pages
show a comparison of breast cancer data
from 1993 to 1997 at Aurora Metro
Region Hospitals.

1997 Breast Cases 5y Stage
Aurora Metro Region by Hospital
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increased, while
Comparing 1997 to 1993 data, the number of Stage 0, I and II cases
s the increased
reflect
likely
trend
Stages III and IV decreased in number. This favorable
awareness of breast cancer and increased screening.
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Patients diagnosed in 1997 were diagnosed at a younger age than
those diagnosed in 1993. The 1993 national statistics show a higher
number of women diagnosed between the ages of 40-49 and 70-79,
but the rest of the numbers are comparable.

1993 Breast Conservation Rates

Breast Conservation

44%

49%

No Surgery
MRM

1997 Breast Conservation Rates

Breast Conservation

56%

43%

No Surgery
MRM

1%

9

The percentage of
breast conserving
surgery in 1997 rose
to 56% from 44% in
1993. Numerous
studies have shown
that for early stage
disease, long-term
survival rates after
lumpectomy plus
radiotherapy are
similar to survival
rates after modified
radial mastectomy
(MRM).

C.)

Location of Cancers within the Breast
Metro vs. Nation
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Nation

Location of cancers within the breast in 1993 and 1997 for Aurora Metro Hospitals.
There was no apparent change in distribution of cancers between reporting periods. The
overall percentage in comparison to the most recent national statistic reveals that most
breast cancers were found in the upper-outer quadrant (UOQ) of the breast.

5-Year Survival Metro Region
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Five-year survival for the Aurora
Metro Region breast cancer cases.
The overall relative survival rate
over a five-year period was
approximately 72% (compared
with 74% for the NCDB 1993
cases). The Metro Region had high
five-year survival for local (20%)
and regional (77%) disease. The
rate at five years for patients with
distant disease was 22%.

Years
• Distant • Regional • Local

National Survival at 5 Years
Cancer Facts and Figures
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local
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When comparing national survival
statistics to the Aurora Metro
Region, the Metro Region had a
higher survival rate for regional
and distant disease and a lower
rate for localized disease. The
lower rate for local diseases may
be due to the older age of women
in the Metro Region.

distant
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pproximately 25,000
mammograms are performed annually
at over 20 Aurora sites in the Metro
Region of Southeast Wisconsin. While
the range of services provided at each
site differs, the goal of high quality
mammography is the same.

All sites throughout the Metro Region
will offer correlative clinical breast
examinations performed by a nurse or
radiology technologist to all patients at
every visit. A training policy is being
developed to ensure competency to
perform the breast examination.
If after a routine mammogram,
additional studies are required to make
a final assessment, the patient will be
contacted and scheduled for the studies
directly by the Radiology Department
in a timely manner.
Considering that they are under great
psychological stress, patients with a
breast problem such as a lump or
discharge will routinely be given the
opportunity to speak with the
interpreting radiologist about their
results and the need for any additional
studies or procedures.
All sites will evaluate the use of
standardized terminology in reporting
findings to referring physicians so that
recommendations for follow-up or
biopsy are clear and concise.
When the breast imaging examination
reveals suspicious findings for which
biopsy is recommended, the results
will be telephoned directly to the
referring physician to expedite
additional procedures.
Implementation of these and other
initiatives at St. Luke’s Medical Center has
resulted in a decrease in the time from an
abnormal mammogram to biopsy, from an
average of 35 days to a median of 7 days.
Similar improvements are being realized
throughout the Aurora Metro Region
in large part as a result of changes in
Radiology Department protocols.
—

The Metro Region Breast Health Task
Force was formed to examine current
practices and formulate a plan for
system integration focusing on clinical
excellence. The workgroup was
comprised of technologists, nurses,
administrators, radiologists and
representatives from Women’s Health
Services and the admitting departments
from Hartford Memorial Hospital, West
Allis Memorial Hospital, Sinai Samaritan
Medical Center, Aurora Medical Group
clinics and St. Luke’s Medical Center and
clinics. The purpose of the task force was
to define and integrate standards of
clinical care and service for breast care
screening across the Aurora Metro
Region. As a result of the group’s
meetings, the following initiatives have
been implemented:
A universal questionnaire was
developed to facilitate accurate and
expedient scheduling of mammograms
as well as to provide important
instructions about the examination.
The scheduling questionnaire, available
for use at all Aurora Metro Region
sites, obtains vital information that
may affect the patient’s mammography
experience and interpretation of
mammographic images.

—

-

—

—

—

—

&etro Region Breast Health Task Force
Mark Wnze1, MD
Co-director, Breast Imaging Services,
St. Luke’s Medical Center
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hue the Haisted mastectomy
once provided the best opportunity for
curing breast cancer, today there are
other options. These options have
evolved in part because increasingly
sensitive diagnostic techniques are
allowing the discovery of breast cancer
at earlier stages than ever before.
Whenever possible, women should
be given treatment choices.
Breast conservation surgery (BCS) is a
treatment that removes the cancer and a
margin of uninvolved breast tissue
surrounding the cancer. Axillary
dissection, radiation therapy, hormonal,
and standard chemotherapy can be added
as indicated to the basic surgery. With the
increasing availability of node mapping,
patients who would benefit from axillary
dissection can be identified.
The term, “partial mastectomy” is
properly associated with BCS since this is
what in reality is being done. “Segmental
mastectomy” is another proper term.
Many refer to BCS as a “lumpectomy,”
but this term does not address the true
magnitude of the surgery. Postoperative
radiation of the breast is an essential part
of the treatment.

Some situations do not permit BCS:
The first and second trimesters
of pregnancy are absolute contraindications to the use of radiation.
Providing it does not delay treatment,
BCS may be possible in the third
trimester, with radiation after delivery.
Multiple lesions or diffuse malignant
appearing calcifications do not allow
the use of BCS. Microscopically
involved margins are considered a
contraindication. Likewise, patients
with an inflammatory cancer are not
candidates.
A history of prior radiation to the
breast prevents further radiation.
Similarly, a recurrence of cancer to
the irradiated breast would not be
amenable to BCS.
A history of collagen vascular disease
is a contraindication because these
patients tolerate radiation poorly.
Tumor size is not an absolute
contraindication to the use of BCS, but
removing a large tumor from a small
breast can result in unacceptable
distortion of the breast. Large tumors
also have a greater chance of localregional recurrence.
A large pendulous breast may make
adjuvant radiation therapy difficult to
deliver with consistency.

—

—

—

—

—

—

The goals of BCS are to achieve localregional control of the tumor and a
cosmetically acceptable breast.

Breast Conservation Surgery
for Breast Cancer
Terence V Roth, MD, FACS
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—

—

Location of the tumor can present
problems. A subareolar tumor may
result in the removal of all or part of
the nipple areolar complex with
resultant deformity. However, nipple
reconstruction techniques can obviate
this objection.
Selection of BCS is not dependent on
tumor size. Histopathology and
lymph node status are also not
determinants. Failure is higher with
multicentricity and the younger
patient.

The rates for BCS vary widely across the
country. It is highest in New England
(40.2%) and lowest in the east south
central (11.5%) which includes Kentucky,
Tennessee, Mississippi and Alabama.
The east north central states which
include Wisconsin, Michigan, Illinois,
Indiana and Ohio had a reported rate of
23.8% in 1992. Note in the graphic
below that the rate of BCS at Aurora
Metro Region hospitals in 1997 was
higher than in 1992.

1
1

-l

ii4

Mastectomy vs. Conservation Therapy
1992 and 1997
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58 43
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•WAMH SLMC SSMC
Modified Radical
Mastectomy

SUMMARY
Advances in early detection have resulted in the option of breast conservation
surgery for more women. The use of BCS should increase in the future as
diagnostic procedures become better able to provide even earlier diagnosis.
The option of BCS should be available to women of all ages. Professional and
public education regarding the efficacy of BCS should help achieve this goal.
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ancer of the breast is not
entirely a disease of women. About 0.9%
of the 180,300 cases of breast cancer in
the United States each year affect males.
An estimated 1,600 men per year are
surprised to find that they themselves
have developed this disease. And how did
they get it? Presumably the same way
women get it; no one knows.
It is easy to speculate that anyone with
breasts can develop this problem, but
perhaps the small size of the male breast
is relatively protective or, more likely, the
hormonal environment that makes the
male breast small is protective. Although
it is not often possible to demonstrate a
hormonal abnormality in men who
develop breast cancer, the balance
between estrogens and androgens may
well be involved. The disease usually
appears at an age when testicular
function is declining, and epidemiologic
studies suggest a higher risk in situations
characterized by a relative excess of
estrogens, such as in males with
Klinefelter’s syndrome, characterized by
hypogonadism and gynecomastia, and
in males with a history of orchitis or
testicular damage. Some degree of
gynecomastia is often found associated
with breast cancers in males, but
gynecomastia is a common finding in
mature males. Recently a genetic
mutation (BRCA2) was found in families
with a high frequency of breast cancer
that predisposes men to the disease.

The signs and symptoms of breast cancer
in men are similar to those in women, i.e.
a lump in the breast or a change in the
nipple such as discharge, retraction or
ulceration. The lump is characteristically
firm and painless. The nipple tends to be
involved early in males because the
tumor almost always develops directly
beneath the nipple, and even a small
tumor quickly reaches the nipple. These
changes in the breast may be associated
with enlarged axillary nodes or other
signs of tumor spread. The breasts of
men are not routinely examined, and
men tend to neglect the signs of breast
cancer, thinking they are of no conse
quence, or are possibly embarrassed by
them. Regular mammograms are also not
recommended for men in view of the low
frequency of the disease. Perhaps for all
these reasons, men have tended to
present with more advanced tumors than
women and with a higher frequency of
spread to axillary lymph nodes. As might
be expected, overall cure rates have not
been as high as for women.
Males with breast cancer have not been
as intensively studied as have females. In
1998, a study of men with breast cancer
was performed at Sinai Samaritan
Medical Center in collaboration with 17
other hospitals in Wisconsin. The study
involved a review of 217 collected cases
diagnosed between 1953 and 1995 and
was published in August 1998 in the
journal, Cancer. The men varied in age

Progress 1h
gale Breast Cancer
William L. Donegan, MD
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from 32-90 years with an average age of
65.4 years, about eight years older than the
average age of female patients with breast
cancer. The study showed that since 1986,
men are being diagnosed at earlier stages of
the disease and are showing improved
survival. ft also showed that men are more
often being treated with modified radical
mastectomy rather than with the more
deforming radical mastectomy, and more
men are receiving systemic adjuvant
therapy as a part of their initial treatment.
The most frequent systemic adjuvant
therapy was hormonal, usually tamoxifen,
but more men are also receiving adjuvant
chemotherapy, often in conjunction with
hormonal therapy. Five-year and ten-year
survivals were 50.6% and 23.7%, which
compare unfavorably with survival of
women. The relatively poor survival of
male patients, however, is largely a
consequence of a high mortality among
elderly males from causes unrelated to
breast cancer. Unrelated mortality
accounted for a third of patient deaths,

principally from heart disease. Other
reports suggest that with appropriate
adjustment for age and stage, the curability
of males approaches that of women.
The mystique of male breast cancer is
diminishing. The more that is learned
about it, the more similar it is to the
disease in women. Indications are that
favorable changes are occurring relative
to male breast cancer, notably earlier
diagnosis and improved prognosis.
Perhaps these changes can be attributed
to heightened public and professional
awareness about the breast cancer
problem in general, with earlier
diagnosis and application to men of the
treatment advances that have improved the
outlook for women. Early diagnosis is the
key to successful treatment. Men should be
aware that they can develop breast cancer,
should examine their breasts periodically
and should seek consultation for any
suspicious signs.

Breast Cancer Sex by Year
Metro Region
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In 1993 and 1997
three cases of male
breast cancer were
seen each year.
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Of the newly diagnosed cancer
cases, distribution by age and
sex shows that a cancer
diagnosis is most frequently
found in those between the ages
of 60-69 for men, and 70-79 for
women. The increased frequency
of women developing cancer
under the age of SO is reflective
of the screenings for women’s
malignancies at an earlier age
than men, i.e. mammograms and
pap smears.
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adiation therapy is part of
primary breast cancer management in
two situations: 1) treating patients with
early stage disease who desire breast
conservation; and 2) to enhance local
disease control as part of combined
treatment in patients with more
advanced but still localized disease.

Early Stage Disease

If a patient is diligent about
mammographic screening, and breast
cancer is diagnosed at an early stage, she
should be rewarded with the least
deforming treatment possible. Patients
with Stage I or II breast cancer can elect
breast conserving surgery and radiation
therapy and be assured of results equal to
mastectomy. Over the last 15 years, there
have been seven controlled studies
worldwide involving over 4,500 patients
who were randomly assigned to either
mastectomy or conservative surgery (i.e.
wide tumor excision, lumpectomy,
quadrantectomy, or segmental
mastectomy) plus radiation therapy
(Table 1). These studies all demonstrate
no difference between the two treatments
for outcome of local control, disease-free
survival or overall survival. Furthermore,
there are literally hundreds of individual
institutions reporting more numerous

patients and many with longer follow-up,
confirming these results. Therefore, the
place of conservative breast management
in early stage breast cancer cannot be
denied, and patients with early stage
disease deserve to be offered this
treatment option without physician bias.
As part of the section of Radiation
Oncology’s continuous quality
improvement, and with the aid of each
hospital Tumor Registrar, the outcome of
conservatively treated patients was
reviewed and is summarized in Table 2.
This included all patients treated at
St. Luke’s Medical Center, Sinai
Samaritan Medical Center and St. Luke’s
South Shore from 1991 to 1993. Over
that three-year period, 154 patients with
Stage 0, I or II breast cancer were treated
in the sections of Radiation Oncology.
The follow-up time was: minimum
48 months, maximum 84 months, and
median 63 months.
Patients who develop a local recurrence
after conservative therapy should be
treated with a mastectomy. Numerous
reports indicate 50-60% disease-free
survival at five or more years follow-up.
Patients who develop a local recurrence
after mastectomy have less than a 25%
chance of five-year disease-free survival
after retreatment.

Radiation Therapy
in Primary Breast Cancer
James Bruckman, MD
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TABLE

Controlled Studies of Conservative Surgery and
Radiation Therapy for Early Breast Cancer
Yrs. of F/U

Study

#

of Pts.

% Local
Control

-‘

¾ DiseaseFree Survival

RT

S

RT

% Overall

Survival
RT

S

S

National Surgical
Adj Breast Project

10

1219

90

92

76

71

59

5$

NCI Milan (Italy)

10

702

96

98

79

78

77

76

Institute Gustave
Roussy (France)

15

179

87

82

75

65

55

45

Danish Breast
Cancer Group

6

905

96

97

79

82

70

66

NCI USA

10

237

82

90

77

75

72

69

European Org. for
Research and
Treatment of Cancer

8

903

no difference

no difference

no difference

10

399

no difference

no difference

no difference

Guys Hosp. Trial
(England)

RT

=

Conservative Surgery and Radiation Therapy

S

=

lI
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Mastectomy

.
2
Metro Aurora Outcome of Conservative Surgery and
Radiation Therapy for Early Breast Cancer
TABLE

% Local
Control

% Disease-Free
Survival

100
98

96
95

29

100

16

94
98

100
88

Stage

# of Pts.

0 (non-invasive)

24
85

1
ha

hlb
Total

:

154

ciII)

96
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Metro Aurora Outcome of Radiation Therapy as part of
Combined Management of Advanced but Localized Breast Cancer
TABLE

Stage

# of Pts.

% Local
Control

% Disease-Free
Survival

I
ha
JIb
lila
IhIb
Total

1
6
22
8
3
40

100
100

100
67

95

55

87
100

63
67
60

95
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Patients eligible for conservative
management are those who elect this
option, have a primary tumor 5 cm.,
and have clinical findings where it is
technically possible to obtain a good
cosmetic result. The technique of
treatment should include removal of all
mammographic abnormalities with
pathologically confirmed tumor-free
margins, axillary lymph node excision,
and irradiation of the entire breast to a
dose of 4800 to 5000 cGy in five to six
weeks. Multicentric disease is not a
contraindication as long as each tumor
can be excised with a clear margin.
Some of the relative and absolute
contraindications for conservative
management of early breast cancer are
pregnancy; small breast size where
excision with clear margins will result in
a poor cosmetic result; prior breast
irradiation; and certain collagen vascular
diseases. Unanswered questions regarding
radiation therapy are: Is a “boost” dose
to the primary site necessary? Does the
axilla require radiation treatment when
lymph nodes are involved? What to do
if the excision margins are involved?
Are there some patients who may not
require radiation therapy after
conservative surgery?
The acute effects that may be seen during
radiation therapy are skin erythema,
tanning, dry or moist desquamation, or
infection; breast edema or tenderness;
and generalized fatigue. These side effects
are usually mild and heal well to result in
good to excellent cosmesis in 80% or
more patients. Long-term complications
are uncommon but may include breast
edema (20% of patients); arm edema

(5%); breast fibrosis (10%); breast pain
(10%); spontaneous rib fracture (1%);
pneumonitis (5%) and shoulder
tightness (10%). Part of the reward of
early diagnosis is an easier psychological
adjustment after conservative surgery
and radiation therapy. Conservatively
treated patients have a positive attitude
about their body image and experience
fewer changes in their feeling of sexual
desirability.

More Advanced Localized Disease

Patients with more advanced but still
clinically localized disease are at a greater
risk of disseminated disease than patients
with early stage disease, and therefore
require combined modality treatment.
The place of radiation therapy is to
reduce the risk of locally persistent or
recurrent disease. Radiation therapy in
this group of patients produces a 50%
reduction in locally recurrent disease.
A few studies claim a survival
improvement with radiation therapy
and a recent British meta analysis found
a 2.6% reduction in deaths when
radiation therapy was part of the
treatment. The outcome of patients
treated in the section of Radiation
Oncology at Aurora facilities are
summarized in Table 3.
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ithough more American women
now die from lung cancer than breast
cancer, statistics still show breast cancer
as the most frequently diagnosed cancer
in American women. Because most
Americans are white, the leading cancer
sites for whites are also the leading
cancer sites for the United States as a
whole. Although the burden of cancer is
high among individuals of all races and
ethnicities, striking differences in cancer
incidence and mortality do exist between
these groups.
According to 1988-1992 data from the
National Cancer Institute’s Surveillance,
Epidemiology and End Results (SEER)
program, breast cancer was the most
frequently diagnosed cancer among
women in all racial and ethnic groups
except Vietnamese Americans, where it
followed behind cervical cancer. White
women had the highest incidence rate.
Despite the lower incidence of breast
cancer in African American women, these
women have the highest breast cancer
mortality rate of all populations studied
in the SEER program. Hispanic and
Filipino women are the only groups
where breast cancer (mortality rates of
15.0 and 11.9, respectively) is still ahead
of lung cancer (mortality rates of 10.8
and 10.0, respectively) as the leading
cause of cancer deaths.

In America, race and ethnicity are
strongly associated with socioeconomic
status, and with related factors such as
education, poverty, and access to health
care. Twelve percent of white Americans
report that they have no health care plan.
This compares to 33% of Hispanic
Americans, 25% of Native Americans,
and 21% of African Americans. Fewer
women in these minority groups have
screening mammograms than white
women.
Mammography finds early breast cancer
and decreases breast cancer mortality
rates among older women. African
American women present with more
advanced stage breast cancer than white
women, and have a decreased five-year
survival rate in comparison (69% vs.
83%). This decreased survival rate
cannot be accounted for by economic
factors alone. Investigators have found
that the lower rate of mammography in
African American women exists across
every level of income. African American
women also have lower stage-specific
breast cancer survival rates than white
women.

-I
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Although genetic and dietary factors
certainly account for some of the
variations in cancer patterns across racial
and ethnic populations, other factors are
probably involved. Health care systems
contain substantial barriers for minority
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Breast Cancer in America’s
Racial & Ethnic kinorities
Gaiy R. Shapiro, MD
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patients. Values, beliefs and attitudes
about cancer vary between racial and
ethnic groups, but fear of cancer, a strong
sense of fatalism, and distrust of the
health care profession are common in
most of America’s minority populations.
Issues related to spirituality, kinship,
language and education may also play a
critical role in the interface between
ethnic and racial minorities and the
medical establishment. Folk beliefs and
practices are pervasive in many minority
communities. They are poorly under
stood, and rarely tolerated by cancer
care specialists.
To overcome these barriers, bridges must
be built between America’s minorities
and its health care institutions,
professionals, and the cancer research
community. Although racial and ethnic
minorities are well represented in
therapeutic cancer clinical trials, studies

that focus on the prevention (i.e. the
recently completed tamoxifen breast
cancer study) and early detection of
cancer have few minority participants.
It is precisely these studies that have the
greatest likelihood of benefiting
America’s racial and ethnic minorities.
Toward this end, Sinai Samaritan
Medical Center helped the University
of Wisconsin Comprehensive Cancer
Center sponsor a National Cancer
Institute regional conference, held this
year in Milwaukee, on Recruitment and
Retention of Minorities in Cancer
Clinical Trials. A wide range of
challenges and issues related to partici
pation in clinical trials, and cancer care
in general, were identified. None was
more important than the need to develop
human connections between health care
providers and minority communities.

Ethnicity 1993
100

50

--

NonHispanic

SLMC

Hispanic

Is

African
American

Native
American

• SSMC

• WAMH

Asian

Other!
Unknown

NATION

More African American patients were seen at SSMC than other Aurora Metro Region hospitals.
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ithough the extent of surgery
required to treat breast cancer has
decreased over the years, operations to
treat breast cancer still have the risk of
significant complications. One of the
most distressing possible complications is
arm lymphedema, which can occur to a
significant degree in 5-15% of patients
undergoing axillary dissection, either as
part of a mastectomy or as breast
conservation. Some studies quote even
higher incidences of this complication.
Because lymphedema can be debilitating,
there are those that argue that axillary
dissections should not be performed in all
women who are diagnosed with invasive
breast cancer. At this time, however, it is
still important to obtain information
regarding the status of axillary lymph
nodes not only in giving prognostic
information, but also to guide decisions
regarding adjuvant therapy.
Tumor size and histology are only general
indicators of the risk of developing
axiflary metastases. A significant
percentage (14-37%) of small invasive
cancers (less than 1 cm.) are found to
have axillary metastases. Physical
examination is notoriously inaccurate in
determining whether or not metastases
are present. If the node status of a
woman with breast cancer can be
accurately predicted, however, without
performing a full axillary lymph node
dissection (ALND), then a significant
number of women (those without lymph

node metastases) can be treated
adequately with a decreased risk of
lymphedema and other potential
complications.
In several trials, lymph node mapping has
shown promise as a technique which can
be used to intraoperatively identify
women who have no nodal metastases
without radical dissection. This could
enable approximately 60-70% of patients
to be spared complete ALND and its
potential complications.
The concept of sentinel lymph node
identification was first developed with
respect to treating melanoma. Morton
and other researches showed that the
sentinel node (the first node in the
lymphatic basin into which the primary
site drains) could be identified accurately
in patients with melanoma. Guliano
(Annals of Surgery, 1994) investigated
the accuracy of using Lymphazurin dye
to detect sentinel nodes in women with
breast cancer. In his pilot trial of 184
breast cancer patients, sentinel nodes
were identified in only 70% of patients.
In his last 100 patients, the sentinel node
was identified in 93% of patients. There
were no false negative nodes, and the
sentinel node was 100% predictive of the
axillary status. These results suggest that
while results of sentinel node biopsies are
accurate, there is a definite learning curve
in using Lymphazurin dye to detect the
sentinel lymph node.

C-)
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Sentinel Lymph Node Study
Wendy Mikkelson, MD
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Krag published in 1993 his experience
using technesium labeled sulfur colloid
tracer with a gamma probe to identify
the axillary sentinel node in women
with breast cancer. A more recent article
by Albertini et a! UAMA, 1996)
demonstrated that combining the two
techniques (vital blue dye and technesium
label tracer with a gamma probe)
increased the accuracy of identifying
sentinel nodes in the axilla. There were
no cases of false negative sentinel node
identification (i.e. other positive axillary
lymph nodes were not found when the
sentinel lymph node was negative).
Interestingly, although the tracer tech
nique helped to identify more sentinel
nodes than the dye technique alone, no
sentinel node identified only by tracer
was found to contain metastases. Also,
some women had tracer going to the
axilla, and their lymph nodes were
negative.
Lymphatic mapping is technically
possible in patients with breast cancer.
Previous studies have demonstrated that
the SLN is probably reflective of the
histological status of the remaining
axillary lymph nodes. Further studies are
needed to confirm the results previously
obtained by Juliano, Krag, Albertini and
others. In the future, lymphatic mapping
and selective lymphadenectomy could
lead to more conservative surgical
treatment for a woman with breast
cancer, and a decreased risk of
lymphedema and other complications.

The Sentinel Node Protocol at St. Luke’s
Medical Center enrolled its first patient
in May 1997. Twenty-one patients
participated in 1997, and 16 patients
(76%) had sentinel nodes detected.
There were no false negatives, where the
sentinel node was negative and other
axillary nodes had metastases. Two
patients (9.5%) had axillary metastases.
The rate of positive metastases was low
because the vast majority of patients had
TI tumors. In both instances where
axillary metastases were found, only the
sentinel nodes had metastases; the other
nodes were negative. In one patient, the
probe detected the sentinel node. In the
other patient, the dye led to the node.
One patient allowed only sentinel nodes
to be removed. Two were found and both
were negative for metastases.
These results are very encouraging, but
must be considered as preliminary.
Hopefully in a year or two, enough
patients will have participated so that the
technique will be shown to be accurate
and reproducible. If sentinel lymph nodes
can be located reliably and do not have
metastases, then the rest of the axillary
dissection will not need to be performed,
and the risk of lymphedema will be
significantly decreased.
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s the practice of high dose
chemotherapy for breast cancer
approaches medical middle-age, its role
in the treatment of this deadly disease
remains a topic of active study.
Previously accepted truths about the
role of dose escalation continue to be
challenged, and yet the number of
autologous bone marrow transplants
(ABMT) for this disease continues to
rise almost logarithmically. Advocates
who had previously lectured on the
importance of early transplant now
champion the role of delayed ABMT in
prolonging life, while others try to
identify pretreatment characteristics of
patients that would make them more
suitable for transplant early in the course
of the disease. As we begin the third
decade of ABMT for breast cancer,
new challenges and new opportunities
continue to present themselves.

The Role of ABMT in Adjuvant Therapy
for Breast Cancer

The role of ABMT for high risk breast
cancer was first defined by Peters and
his group at Duke University. In a
historically controlled series, they
identified a high risk population of
women with breast cancer who
demonstrated involvement of more
than 10 axillary lymph nodes. In a nonrandomized, historically-controlled trial,
this group was able to show a substantial

improvement in disease-free and overall
survival. While widely quoted and
criticized, this trial became the basis for a
variety of follow-up studies of transplant
for high risk patients.
Since the original report, several
developments in the field have occurred
which may ultimately change the practice
of ABMT in this disease. First, standard
adjuvant therapy for breast cancer has
improved, and while women with 10
or more positive lymph nodes remain at
high risk for recurrence, the survival
statistics have gotten better. Secondly,
earlier detection of breast cancer has
reduced the number of high risk patients,
although the percentage of recurrences
has remained relatively constant in the
last five years. Third, in what amounts to
a rather extensive reversal of their prior
publication, Peters et. al. have recently
published a smaller institution study
which purportedly showed a benefit for
delayed, as opposed to immediate,
transplant for breast cancer. This study,
though widely quoted, has not been
repeated and remains an uncontrolled
study with small numbers of women.
The only published randomized trial
of bone marrow transplant versus
conventional therapy in the adjuvant
setting was published from South Africa
a few years ago. This showed a
significant improvement in disease-free
and overall survival for high dose
therapy. This study differed substantially

Autoloou Bone Marrow Transplant
for Breast Cancer
Robert Taylor, MD
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from current practice in that trans
planted patients received relatively little
pre-ABMT chemotherapy and moved
quickly to transplant after diagnosis.
Nonetheless, the study was well
randomized, and groups were well
controlled for risk factors.
The largest multi-institution randomized
controlled trials have recently closed to
accrual. Initial review of data is not
expected until the year 2002, and it is
likely that the data will be difficult to
interpret because of selection bias, but
the results will be the best way to
evaluate this difficult and emotionallycharged subject.
Despite the dearth of large trials, several
trends and truths may be gleaned from
current available data. First, ABMT
remains an extremely effective method
of inducing complete remissions (CR).
Secondly, high dose therapy can
overcome drug resistance in selected
patients and may be able to salvage
patients with “resistant disease.” Finally,
ABMT earlier in the course of the disease
may be more useful than late transplant
in patients with appropriate risk factors,
although this needs confirmation in a
controlled randomized trial.
ABMT for Metastatic Breast Cancer

Metastatic breast cancer is largely
considered an incurable disease. While
responses to chemotherapy have been
frequently noted, CRs remain elusive and
long-term, disease-free survival is rare.
In addition to the obvious problems with
metastatic disease in multiple sites,

patients with this disease are often in
poor clinical condition, and in many
cases have been heavily pretreated in the
adjuvant setting. This tends to make
them poor candidates for high dose
therapy for metastatic disease, and in fact
the outcome of ABMT is poor in all
reported series for this group. However,
a high percentage of such patients will
obtain a complete remission after
transplant, although it may be of limited
duration. This suggests that high dose
therapy is able to overcome disease
resistance, but that microscopic disease
remains. Identifying microscopic disease
and dealing with it early on may be
critical to long-term, disease-free survival
after ABMT.

Current Research and Future Strategies

Our current clinical trials with ABMT at
St. Luke’s Medical Center involve the use
of post-transplant immunomodulation to
eradicate microscopic residual disease.
While ABMT is highly effective in
decreasing bulky disease, it is also
destructive to the immune system. Both
cell mediated and antibody mediated
immune surveillance is suppressed after
transplant for variable lengths of time.
This effect may paradoxically present a
“window of opportunity” for malignant
cell proliferation. If one could eliminate
this window by adding cytotoxic T cells,
immune surveillance might be restored,
and assuming appropriately targeted
therapy is used, microscopic disease
could be eliminated when it is in its
lowest volume.
Our clinical protocols are testing this
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hypothesis by utilizing activated
autologous T lymphocytes and the
cytokine Interleukin-2 to reduce or
eliminate minimal residual disease in
patients with metastatic breast cancer.
In this process, activated T cells are
produced from samples of blood
obtained at the time of stem cell
collection for transplant. These are then
incubated with cytokines, and their
numbers are expanded in vitro. After
bone marrow transplant, the cells are
reinfused over a matter of several weeks
with continuous infusion Interleukin-2.
This procedure, done on an ambulatory
basis, is well-tolerated and nontoxic.
Preliminary data suggests that in addition
to being safe, this procedure may extend
disease-free survival post ABMT. Final
analysis is pending and should be
available soon.
Post-transplant manipulation with other
agents is being contemplated as well.
An upcoming trial will use co-activated
T cells which may be more specific and
therefore more effective in reducing
microscopic malignant cells. The
availability of the monoclonal antibody
Herceptin, which recognizes the
HER2-neu oncogene, will present
another approach to post-transplant
conditioning. This antibody may be
especially useful post AMBT, since it
addresses a subset of the breast cancer
cells not previously thought to be
sensitive to high dose therapy. Using this
in combination with cellular therapy
could present a powerful combination
against this deadly disease.
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Conclusions

The role of high dose therapy and
autologous bone marrow transplant for
breast cancer continues to be actively
investigated. New techniques to
potentiate the effects of bone marrow
transplant and pre- and post-transplant
therapies are entering the clinical arena
and should be available to patients in the
near future. Redefining and refining the
use and usefulness of autologous bone
marrow transplant remains a critical goal
for the next decade and should help in
the fight against this disease.

‘

any factors, both genetic and
non-genetic, are involved in the
development of cancer. For years, it has
been recognized that some families have
a clustering of individuals with breast
and ovarian cancer. These families have
been considered to have a genetic
predisposition to develop cancer.
In recent years, two major susceptibility
genes, BRCA1 and BRCA2 (BR east
CA ncer), have been identified as
responsible for approximately 90% of
inherited breast cancer. This article will
focus on these two major genes, dis
cussing some of the molecular diagnostic
and genetic counseling issues associated
with BRCAI and BRCA2 genetic testing.
Since hundreds of the approximately
50,000-100,000 genes that make up the
human genome must code for the
formation and function of the breast and
ovary, it is likely that many other, yet to
be identified genes also play a role in the
development of these cancers. It has been
estimated that seven percent of all

(inherited and non-inherited) breast
cancer and 10% of all ovarian cancer are
associated with inherited mutations in the
BRCA1 or BRCA2 genes. BRCA1,
located on the long arm of chromosome
17, was the first major breast cancer gene
to be mapped. The gene was discovered
in 1990, and by 1994 scientists had fully
determined its DNA sequence. BRCA2,
located on the long arm of chromosome
13, was the second major breast cancer
gene to be identified. The complete
sequence of this gene was determined
in 1996.
In addition to breast and ovarian cancer,
individuals who have BRCA mutations
are at increased risk for developing other
cancers such as colorectal and prostate
cancer. Additionally, women who carry a
BRCA mutation are at increased risk to
develop a second cancer. Men with
BRCA2 mutations have an increased risk
to develop breast cancer and other types
of cancer as well.

Genetic SusceptiLility Testing
for Breast and Ovarian Cancer;
BRCA1, BRCA2 Testing
Jamie Israel5 MS
Genetic Counselor, Great Lakes Genetics

Christine Bryke, MD
Genetic Counselor, Great Lakes Genetics
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The BRCA1 and BRCA2 genes are
tumor-suppresser genes that play an
important role in the regulation of cell
growth. Males and females normally
possess two copies of each of these genes.
Individuals who have hereditary breast
or ovarian cancer, or have an increased
risk to develop cancer secondary to these
genes, have a single germline mutation in
either BRCA1 or BRCA2. The develop
ment of cancer results from a “two hit”
process. The first hit is the germline
mutation the individual was born with.
The second hit is a somatic or acquired
mutation in the other gene of the pair.
Once both genes of the BRCA pair are
mutated, the gene will allow uncontrolled
cell growth and thus, cancer will develop.
Germline mutations in the BRCA1 and
BRCA2 genes are passed from parent
to child in a dominant pattern of
inheritance. Therefore, there is a 50%
chance for a person who has a germline
BRCA1 or BRCA2 mutation to pass this
gene on to each of his/her children.
Women may inherit a BRCA gene from
either their mother or their father. We
often think of breast cancer as being
inherited from a woman’s mother’s side
of the family. However, the gene has an
equal chance of being inherited from
either parent.
A mutation in a gene results when DNA
base pairs have been substituted for one
another, are missing, or are otherwise
rearranged. Some genes have one specific
mutation that causes a disease. For
example, the A to T substitution in
codon 6 of the beta globin gene produces
100% of sickle cell anemia. There are
other genes that have one common
mutation that is responsible for a large
proportion of the cases of a particular
disease. An example of this is the delta
F508 three base pair deletion in the
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CFTR gene which accounts for
approximately 70% of cystic fibrosis
gene mutations. Most genes, however,
have numerous different mutations that
cause a particular disease. The more
disease-producing mutations a gene has,
the more complex the molecular testing
is to identify an abnormality in that gene.
This, unfortunately, is the case for the
BRCA genes.
Hundreds of deleterious gene mutations
have been identified in BRCA1 and
BRCA2. Both are large genes, with
BRCA2 twice the size of BRCA1.
A mutation in either of these genes often
leads to premature truncation of the
BRCA1 or BRCA2 protein product,
leading to a protein that cannot function
normally to suppress cell growth.
Mutations have also been identified
which do not adversely affect protein
structure but may affect the stability
of the protein. To confidently rule in or
exclude the presence of a cancerproducing mutation in the BRCA genes,
the entire sequence of both genes must
be analyzed. Due to the large size of
these genes, especially BRCA2, the
analytical strategy depends upon dividing
up the genes into many small sections
that can be examined by current DNA
sequencing robotics.
Three specific BRCA mutations have
been found in high frequency in women
with breast cancer who have Ashkenazi
ancestry. BRCA gene testing for
individuals in this population often starts
with the simpler process of excluding
these mutations. If no mutation is
identified, then the full BRCA1 and
BRCA2 gene sequencing is performed.

-

.—

At the present time, full sequence BRCA
analysis is commercially available and
costs approximately $2,400. The test
most often is run on blood samples,
but can be performed an any tissue,
sometimes even autopsy tissue in paraffin
blocks. The cost is high due to the
technical complexities of sequencing two
large genes. If a BRCA mutation is
identified in an affected family member,
then targeted mutation analysis looking
for that specific mutation can be
performed for other risk relatives. The
cost of this rather straightforward
molecular testing is approximately $250.
The cost of the three BRCA mutation
panel for Ashkenazi Jewish women is
intermediate in price between the full
sequencing analysis and the specific
mutation analysis.
Occasionally, a BRCA gene DNA change
will be found in a patient that has not
been previously associated with breast
or ovarian cancer. In these cases it may
not be entirely clear whether the base
pair alteration is disease-producing or is
a benign change in the DNA base pair
sequence. Thus, genetic testing will not
always be able to definitively determine
whether or not a breast cancer patient
has a mutation in one of the BRCA
genes. At the present time, a listing of
identified BRCA1 and BRCA2 mutations
is being maintained through the Breast
Cancer Information Core (BIC). This
database is essential for the correlation
of clinical data with mutational analysis.

individual, it can be looked for in other
family members. Relatives who are also
found to possess the mutation will have a
significantly increased risk to develop
breast or ovarian cancer. Most
individuals, but not everyone, who
possesses the mutant BRCA gene will
develop cancer. These individuals can
then have close medical follow-up for
possible tumor development. This way,
the familial tumors can hopefully be
discovered early when they can most
effectively be treated. Family members
who are found not to have the BRCA
mutation will be relieved to not have a
significantly increased risk for the
familial tumors. They will not need the
aggressive tumor surveillance required by
affected family members, family members
who are found to have the gene, and
other family members who have not had
genetic testing.

In some families, an affected family
member(s) is not available or is not
interested in BRCA testing. In these
situations, BRCA testing can be offered
to an unaffected individual. However, if
no BRCA mutation is identified, this may
be falsely reassuring. One could not be
sure that the unaffected person and the
affected relative(s) do not share one of
the many other genes responsible for
breast cancer. There are also cases where
an affected family member has BRCA
testing and no mutation is identified.
Therefore, BRCA testing in an unaffected
individual in the family would be
uninformative. In both of these above
Although BRCA gene sequencing analysis situations, risk assessment can best be
determined based on the family history
can be performed for anyone concerned
data. Close tumor surveillance would still
about their risk for developing familial
be indicated given the individual’s family
breast or ovarian cancer, the testing is
history information.
most informative if an affected family
member is tested first. If a BRCA
mutation is found in the affected
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Over the last several years, research
studies have been performed in an effort
to identify families at an increased risk to
have BRCA mutations. Modeled
probabilities have been established in
categories of 1) clinical diagnosis (breast
or ovarian cancer); 2) age of onset with
breast cancer less than age of 50
considered early onset and ovarian cancer
at any age; 3) number of affected relatives
(with breast cancer only, or breast and
ovarian cancer on both mother’s and
father’s side); and 4) ancestry of the
individual. A number of studies have
found an increased risk of BRCA
mutations in individuals of Ashkenazi
Jewish ancestry.
Based on the above categories, a recent
study has determined that individuals
who themselves have been diagnosed with
both premenopausal breast cancer and
ovarian cancer have an approximately
88% chance of identifying a BRCA
mutation, while individuals who develop
breast cancer prior to the age of 50 and
have at least one relative with breast
cancer or ovarian cancer (at any age)
have at least a 20% probability of
carrying a BRCA mutation.
In general, the following histories
indicate that there may be a high risk
of identifying a BRCA gene mutation in
the family:
Individuals who have two or more
close family members (mother, sister,
daughter, aunt or cousin, maternal or
paternal side) with premenopausal
breast cancer or ovarian cancer at
any age.
Women with a diagnosis of
premenopausal breast cancer and any
relative with premenopausal breast
cancer or ovarian cancer at any age.
Women with a diagnosis of ovarian
cancer and any relative with
premenopausal breast cancer or
ovarian cancer at any age.
Individuals who have a relative
with a known BRCA mutation.

—

—

—

—
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Individuals who are considering genetic
susceptibility testing for breast cancer
frequently have many questions. They
often include: What is my risk for
developing cancer? What is the
probability of identifying a BRCA
mutation in me? What are the treatment
options if a BRCA mutation is identified?
What are the limitations, risks and
benefits of BRCA testing?
They also want to know about the cost of
the test, insurance coverage, and if there
is the possibility for insurance (health, life
and disability) discrimination. All of these
concerns can be addressed in genetic
counseling prior to testing. In fact, it is
strongly recommended that anyone
undergoing genetic testing for cancer
gene susceptibility testing have genetic
counseling first. A counseling session
usually begins with the genetic counselor
obtaining a detailed three-generation
pedigree from the patient. Using this
family history, the counselor then
estimates the patient’s risk to be
carrying a BRCA cancer gene. Sometimes,
medical records of family members need
to be reviewed to determine exactly what
type of cancer a relative had, and what
the age of onset was.
Some individuals who consider BRCA
testing may discover through genetic
counseling that their risk of developing
cancer or identifying a BRCA mutation
may actually be lower than they
anticipated. Genetic counseling is a time
when issues and misconceptions
regarding genetic testing are addressed.
The service should be provided by a
board certified genetic counselor or other
health care provider who has a good
understanding of genetics, molecular
testing, and the clinical and personal
issues related to cancer.
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ore and more frequently women’s
breast cancers are identified early with
routine screening mammography. Because
these women usually have node-negative
disease and small tumors, physicians
currently have no way of knowing which
women should receive adjuvant systemic
drug therapy after surgery.

MORPHOLOGIC
PROGNOSTIC MARKERS

Lymph Node Status

Lymph node status is the most powerful
prognostic indicator for breast cancer, and
has the strongest influence on treatment
failure rates. Recently, with the advent of
better diagnostic and screening tools, only
In addition to reporting the presence of
about 30% 35% of women have
infiltrating ductal carcinoma, the diagnostic
metastatic disease to the axillary lymph
pathologist has the responsibility of
nodes at diagnosis. Axillary lymph node
providing the physician with additional
status is a strong predictor of patient
morphologic information needed for esti
survival in that the greater the number of
mating prognosis and selecting treatment.
positive lymph nodes, the more likely the
The prognostic discriminates that have been
patient is to die within five years. The most
proposed for invasive ductal carcinoma are
useful groupings have been found to be
numerous. Prognostic markers can be
those patients with a) negative nodes; b) one
important aides to physicians in identifying
to three involved nodes; c) four to nine
patients suitable for adjuvant treatment. An
nodes; d) ten or more involved
NIH consensus development conference held involved
nodes. The percent of overall survival by
in June, 1990 concluded that “Prognostic
nodal status varies according to how many
factors should be used to provide an
lymph nodes are involved with metastatic
estimate of risk of recurrence in women
carcinoma. Clinical and pathological
with early-stage breast cancer.” A useful
s can also be used to estimate the
prognostic factor is one that has been shown finding
risk of lymph node metastases for patients
to have a significant and independent
where carcinoma is less than 2 centimeters.
predictive value in clinical trials. A number
A recent study utilizing multivariate analysis
of prognostic factors for breast cancer,
found that vascular invasion, tumor
mainly histopathological or clinical, have
palpability, nuclear grade and tumor size are
been developed and widely used over the
all independent predictors of axillary lymph
last 20 years. More recently, biochemical
node metastases for patients with T1 breast
and molecular markers have been proposed
carcinoma. These features may be partic
which could be used for prognosis, either
ularly helpful in conjunction with sentinel
alone or in combination.
lymph node status.
-

Tumor Size

Although lymph node status has been
established as an important predictor of
treatment failure, the size of an infiltrating
carcinoma is independently significant with
patient groups stratified by the number of

Pathology and Prognostic Markers
in Breast Cancer
Jorge G. Pellegrini, MD
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positive nodes. The National Surgical
Adjuvant Breast Project (NSABP) data at
5 and 10 years of follow-up has continued
to show the importance of tumor size, with
lesions less than 2 centimeters faring
significantly better (when controlled for
nodal status). It is particularly important to
identify invasive carcinomas that are less
than 1 centimeter in greatest dimension
since patients with such carcinomas and
negative lymph nodes have an excellent
prognosis. In addition, microinvasive
carcinoma (invasion limited to no more
than 5 millimeters) has a survival rate of
greater than 99%. Survival decreases with
increasing tumor size, and there is a
coincidental rise in the rate of axillary
node metastases.
Histologic Grade

Many studies have documented the
prognostic importance of the grade of
invasive carcinoma independent of nodal
status. All invasive carcinomas should be
graded and identified as to the special type
of carcinoma by name. The Association of
Directors of Anatomic and Surgical
Pathology recommend the grading scheme
of Scarff-Bloom-Richardson for grading
invasive breast carcinomas. This grading
scheme is based on tubule formation,
nuclear grade and mitotic rate. This system
is easy to use, reasonably reproducible and
has been clinically validated. Moreover, it
has been proven to provide significant
prognostic and therapeutic information.
As recent report indicates that a higher
histologic grade predicts an increased
incidence of distant metastasis but not
axillary metastasis or local recurrence.

Angiolymphatic Invasion

Some but not all studies have shown an
increased risk for distant metastases when
intralymphatic or vascular tumor emboli are
present in vessels outside the main tumor
mass. Investigators at the Institute Curie in
Paris have reported a strong trend for
lymphatic invasion to be correlated with
local recurrence in patients treated by
lumpectomy.
Margins of Resection

Recent reports from Stanford and the Joint
Center in Boston as well as others have
shown that attainment of negative surgical
margins initially or at re-resection is the
most significant predictor of local control
after breast conserving therapy by means
of lumpectomy and radiation therapy.
Schnitt and colleagues have also shown
that margins are highly correlated with
recurrence for patients treated with breast
conserving procedures and extensive
intraductal carcinoma does not predict a
significant risk for recurrence when margins
are negative.
BIOLOGICAL MARKERS
OF PROGNOSIS

Extent of Ductal Carcinoma in Situ
Associated with Invasive Ductal Carcinoma

In a 1994 report, it was found that
extensive intraductal carcinoma did not
predict a high recurrence rate if the margins
were negative for both in situ and invasive
carcinoma.
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Over the last decade, more than 100
potential biologic prognostic and predictive
factors have been touted in medical
literature, but practically none of these
discriminate risk categories independent of
morphologic predictors or have been
characterized well enough to be used
routinely by clinicians. Guidelines for
evaluating these molecular biologic factors
have been published and there is basic
agreement that for a factor to be used in
patient care it should be technically and
clinically validated and influence clinical
decision making. The only factors which
come close to meeting these guidelines are
the size of the tumor, histopathologic grade
and lymph node status (for prognosis) and
ER/PR determinations (for predicting
response to therapy). In spite of these, three

.

markers have emerged as the most likely to
meet the guidelines outlined above. These
markers are HER2Ineu(CerbB2), DNA and
S-phase. As in the past, grade, size, and
nodal status outperform any other
prognostic indicators and ER/PR is the best
predictive factor.
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Oncogenes

Insight into genetic changes involved in the
development and progression of malignant
neoplasms has been gained from the study of
oncogenes. In human tissues, amplification
of HER2 was found to be associated with
adenocarcinomas especially mammary
carcinoma. Some authors have found that
Hormone Receptors
HER2 is present more often in tumors larger
red to
These proteins bind and mediate the cellular than 2 centimeters when compa
smaller tumors. A similar trend was
effects of circulating hormones. The most
observed in a comparison of tumors larger
in
breast
rs
extensively studied recepto
and smaller than 5 centimeters. Most
carcinoma bind estrogen and progesterone
investigators have found no association
ting
infiltra
Among
receptors (ER and PR).
between HER2 and axillary lymph node
duct carcinomas there is an inverse
status. In one report, positive lymph nodes
relationship between grade (nuclear or
were more often present when the primary
histological) and ER/PR positivity. ER and
tumor had three or more copies of the
PR are highly associated with age at
HER2 gene than when there were fewer
diagnosis being positive significantly more
copies. Other investigators did not detect an
al
than
nopaus
postme
often in tumors from
association between copy number and nodal
in tumors from premenopausal women.
status. Another study found HER2 more
often in carcinomas with poorly
n
estroge
PR
is
of
Since the expression
differentiated nuclear grade. Several studies
are
mas
carcino
sitive
regulated, most PR-po
reported a statistically significant trend for
also ER-positive. Less than 10% of
in tumors
carcinomas are ER-negative and PR-positive. more frequent detection of HER2
grade,
gical
Patients with ER- or PR-positive carcinomas with poorly differentiated histolo
whereas others found no significant
tend to have a significantly longer diseaseassociation with histologic grade. Four
r
recepto
with
women
free survival rate than
studies reported a greater frequency of
ER
the
of
impact
negative tumors. The
HER2 in hormone receptor-negative tumors,
status of the primary tumor on prognosis is
tion
greatest in patients with axillary lymph node but others found no significant associa
between HER2 and the detection of estrogen
metasteses especially when multiple lymph
or progesterone receptors in the carcinoma.
nodes are affected and substantially less
important in node-negative patients. Similar
One group found that greater than twofold
results have been reported for PR.
amplification occurred significantly more
frequently in women with metastases in
ER is an important determinant of response
three axillary nodes than in those with fewer
to hormone therapy in patients with
ed.
recurrent carcinoma. If possible, the analysis than three or no lymph nodes involv
Amplification found in 40% of these
should be performed on a recurrent lesion
patients was more frequent in women with
the
n
betwee
sion
since variation in ER expres
four or more than in those with one to three
primary tumor and metastases occurs in
involved nodes. Analysis of recurrence free
about 25% of cases.
and overall survival revealed a significantly
less favorable outcome among the nodepositive women with fivefold or greater
amplification.
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The relationship of HER2 expression to
prognosis in patients without axillary lymph
node metastases has been extensively
investigated. A substantial majority of
studies found no significant association with
recurrence or with survival. On the basis of
this data, it is reasonable to conclude that
HER2 expression as currently determined is
not a significant prognostic factor in nodenegative patients. Multivariate analysis
revealed that amplification of HER2 was
a statistically significant prognostic factor,
second in importance only to axillary lymph
node status. Other studies have found
amplification of HER2/neu oncogene in
about 20% to 30% of breast and ovarian
tumors and suggested that these tumors
belong to patients with shortened diseasefree and overall survival. Another study
suggested that CerbB2 may be a marker for
identifying patients who are most likely to
benefit from adjuvant chemotherapy.
Flow Cytometiy and Growth Rate

In 1979, Atkin and Kay described the
relationship of modal DNA values to
prognosis in 1,465 diverse malignant
tumors, including some breast carcinomas.
DNA ploidy distributions in breast
carcinomas measured by flow cytometry
have shown that tumors with diploid DNA
distribution tend to be estrogen and
progesterone receptor-positive whereas
receptor negativity has been associated with
aneuploidy. Pathological studies have shown
a close correlation between cytological
grading of tumor nuclei and DNA ploidy
analyzed by flow cytometry. Low-grade
tumors typically exhibit near-diploid DNA
whereas aneuploidy is most pronounced in
tumors with high grade nuclei.
Flow cytometry also provides a simple
method of determining the proliferative
fraction (S-phase fraction or SPF). It has
been observed that proliferative activity
reflected in the SPF is correlated with ploidy
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to the extent that diploid carcinomas tend to
have a lower SPF than aneuploid lesions.
Tumors with a high SPF tend to be ER
negative. SPF has been found to correlate
with the histological differentiation of duct
carcinomas and with nuclear differentiation.
While some investigators have reported that
ploidy and/or SPF did not correlate with
nodal status at the time of initial treatment,
others found a high SPF in node-positive
compared with node-negative patients.

1

4
4

Several reviews of the prognostic significance
of ploidy and SPF have been published
recently. Because of the close correlation
between tumor grade, SPF, and ploidy, the
significance of any one of these features as
an independent prognostic factor is difficult
to ascertain. Whereas patients with tumors
that have a diploid DNA index tend to have
a more favorable prognosis, the magnitude
of this advantage compared to tumors
showing aneuploidy is small. An association
between high SPF and increased risk for
recurrence has been documented in most
studies, but others have failed to detect this
relationship.
CONCLUSIONS
It is safe to predict that the current menu of
traditional prognostic markers will expand
further with the addition of new protein and
molecular prognostic markers. Since the
analysis of many markers per patient is
costly, appropriate clinical trials should be
designed to select the ones that carry
independent value and to design panels that
would improve the markers’ prognostic
power. The prognostic value of an individual
marker tends to be low; however, the proper
use of optimal panels will most likely result
in better patient survival outcomes through
subgrouping and selection of the appropriate
time and type of postsurgery adjuvant
therapy.
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he Wisconsin Women’s Cancer
(WWCCP) is a
Program
Control
13 suburban public
among
partnership
in Milwaukee County
departments
health
Hospital to
Memorial
Allis
and West
uninsured
and
d
under-insure
reach
women for mammography and cervical
screening. The City of Milwaukee also
has a WWCCP project, and we work
collaboratively to avoid duplication of
services.
The West Allis Health Department is the
lead agency and fiscal agent for the
suburban project. Funding is from a
grant through the State of Wisconsin
WWCCP which is part of the Center
For Disease Control National Breast and
Cervical Screening Program. The West
Allis Health Department has contracted
with West Allis Memorial Hospital to
conduct outreach and provide service in
the 18 community areas of Milwaukee
County; organize the health care
community into a network of providers;
and provide a staff person to function
as project coordinator.
This project has been operational since
April 1994 and began screening services
in October 1994. The program’s target
group is women 50 and older, whose
income is at 200% of poverty or less.
Outreach efforts in each community,
providing essential screening support,
referral and follow-up support services
to residents, are the key components of
the program. Aurora providers for the
WWCCP program include St. Luke’s

South Shore, St. Luke’s Medical Center,
Sinai Samaritan Medical Center, West
Allis Memorial Hospital, Mobile Testing,
Aurora Medical Group-Wauwatosa,
St. Luke’s New Berlin Health Care
Center, Franklin Family Medical Clinic,
and Clarke Square Family Health Center.
Some of the facilities offer both mammo
graphy and Pap services. If not, other
providers such as Planned Parenthood
are also used. Providers are reimbursed
at Medicare rates for screening and
diagnostic mammography, ultrasound
and fine needle aspiration. Specific office
visits are also reimbursable. Pap tests and
colposcopy are also covered services.
In 1997, 308 women were screened
as WWCCP clients a 44% increase
over 1996, although the goal was to
screen 500.
—

Re-screening previously eligible women
and recruitment of new eligible women
is a continuous process. Eligibility is
based on age and income, and
participants must be re-qualified each
year. In 1997, the target was women 50
and older, with a small amount of
funding available for women 40-49 years.
Previously screened women are tele
phoned to be re-qualified for their next
mammogram and are advised to make
an appointment. If the woman does not
respond, at least two letters are sent as a
follow-up reminder. Re-screening rates
for 1997 averaged 59%.

‘Wsconsin M1omen’s Cancer
Control Program
Nancy Rhodes, RN, BSN
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Follow-up for women who need
additional services is the responsibility
of the provider. The WWCCP coordi
nator assists in this area in cooperation
with the local health department.
The coordinator provides assistance in
helping a patient with follow-up services
as needed. No treatment services are
covered under this program. Aurora
facilities have been cooperative in
assisting patients with treatment when
disease is found. To the coordinator’s
knowledge, no patient has gone
without treatment.
A small fund was established in
September 1996 to assist under- and
uninsured women with some expenses.
Revenue for the fund is generated
through the sale of breast cancer
awareness pins and a quilt raffle for
two handmade quilts at the WWCCP
booth at the Wisconsin State Fair. This
fund is available to underserved women
throughout the state by referral from the
local WWCCP coordinator. In 1997, we
assisted with partial payment of bills for
39 women at an average of $88 per bill.

Although we have the ability and
payment source to screen more women,
a major challenge has been locating the
target group of women in the 50-65 year
age range who are at 200% of poverty.
Each health department has tried a
variety of approaches i.e. working with
community organizations like the
Salvation Army, articles in community
newsletters, direct mail, flyers, health
fairs, letters to physicians in one
community, mobile mammography, Pink
Ribbon Month in October which targets
churches, meal sites and beauty shops,
and most recently, presentations at
selected employers.
Our challenge continues as Medicare
began to pay for annual mammograms in
1998, and the target age group will be
50-64 years of age. Our goal for 1998 is
to provide screening services to 500
women in suburban Milwaukee County.
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Clinical Trials ECOG, RTOG and BCPT
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Aurora Health Care hospitals offer patients a wide range of clinical protocols.
Patients are eligible to be enrolled in major cooperative study groups dedicated
to increasing the survival and improving the quality of life of patients with
cancer. Studies conducted in 1997/1998 directed at breast cancer are as follows.

Eastern Cooperative
Oncology Group Trials (ECOG)

Nancy Briggs, RN, MSN, OCN Coordinator
Gary Shapiro, MD Principal Investigator
-

-

rD

Enrollment of women and minorities has
continued to be an area of strength for
the research program at Sinai Samaritan
Medical Center. The Medical Oncology
Clinic at SSMC is an affiliate of the
University of Wisconsin’s Comprehensive
Cancer Center. In conjunction with the
Eastern Cooperative Oncology Group
(ECOG), more than 60 clinical trials are
available to patients, addressing a wide
variety of cancers and symptom
management. In 1997, the following
breast cancer studies were available:
A four-arm study comparing two- or
three-week scheduling of chemother
apy drugs in Stage Il/lilA breast cancer
(Phase III trial);
A two-arm study of chemotherapy
drugs given in three-week intervals
for node positive or high risk node
negative patients (Phase III trial);
A three-arm study comparing three
chemotherapy drugs followed by a
comparison of weekly vs. three weekly
doses of chemotherapy for metastatic
breast cancer.
Other research studies have made
drug treatments that are not currently
commercially available including
suramin, marimastat, PSC 833, and
oral 5-FU accessible to patients.
Symptom management studies address
mucositis, pleural effusions, diarrhea
and pain management.
—

—

—

—

An ongoing priority has been raising
patient/family awareness of the
availability of clinical trials and the
opportunities they provide to receive
state of the art care. Increasing numbers
of patients and family members have
recognized the benefits of participating in
clinical research. ECOG’s web site, an
educational resource for patients and
families, has been expanded to include
more information for the general public,
explaining what clinical trials are and
what ECOG is all about. Internet
access is available in the Medical
Oncology Clinic.
Radiation Therapy
Oncology Group Trials (RTOG)

Monique Swiecichowski, RN, BSN
Coordinator
MD Principal Investigator
Pincus,
Mitchell
-

-

The Radiation Therapy Oncology Group
(RTOG) was initially organized in 1968
as a national clinical cooperative group
for the purpose of conducting radiation
therapy research and cooperative clinical
investigations. It is now a multi-center
cooperative organization that includes
27 full member institutions and more
than 180 affiliate institutions in the
United States and Canada.
The RTOG is dedicated to increasing the
survival and improving the quality of life
of patients with malignant diseases;
preventing second and subsequent
malignant tumors; demonstrating the
contributions of new modalities to the
therapy of cancer; and seeking greater
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understanding of the biology of several
types of cancer. Since its inception, the
RTOG has activated 350 protocols and
accrued a total of about 60,000 patients
to help meet these goals. In January
1997, RTOG activated the first breast
protocol in 14 years. RTOG 97-02 is
designed to determine the net value of
radiation therapy in patients 70 years or
older who have carcinoma of the breast
that is 2cm; are without palpable
axillary nodes; and who all receive
tamoxifen. This intergroup trial
originated in the Cancer and Leukemia
Group B (CA LGB), and has been
available to St. Luke’s Medical Center
patients since May 1996.
Palliative treatment is a significant
portion of cancer care, with an estimated
$900 million spent each year, mostly for
painful osseous metastases. Radiation
therapy will provide almost 90% of these
patients with at least some improvement
in their pain and half with complete pain
relief. However, there is disagreement as
to the most effective treatment schedule
and total dose. RTOG 97-14 compares
a single fraction (8 Gy) to 10 fractions
(30 Gy total) for breast (and prostate)
cancer patients with bone metastases.
Frequency and duration of pain relief,
quality of life, cost-effectiveness, and
incidence of secondary pathologic
fractures will be compared.
Another study which was available to
St. Luke’s radiation therapy patients this
year, was a Phase III randomized study
comparing prophylactic topical agents for
radiation-induced skin toxicity. RTOG
97-13 was made available to many
women with newly diagnosed breast
cancer who had breast-conserving
surgery only, as prior treatment. This
study hoped to determine whether Biafine
was most effective in preventing
dermatitis; to determine maximum
reported severity, time to occurrence, and
duration of dermatitis; to compare
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patients’ quality of life between inter
ventions; and to assess product toxicities.
St. Luke’s Radiation Oncology also
participated in a national study on
estrogen replacement therapy coordinated
by the University of Texas M.D.
Anderson Cancer Center. This study will
examine the benefit of postmenopausal
administration of estrogen related to
quality of life, reduction in cardio
vascular morbidity/mortality, and
reduction in the morbidity/mortality
associated with osteoporosis. Due to the
benefits and the lack of any available
data regarding estrogen in women with a
background of breast cancer, a
prospective randomized control trial is
needed. Any woman, in or out of the
Aurora system, with Stage I or II breast
cancer (ER negative and disease free for
two years or ER unknown and
disease free for 10 years) who has
documented menopause could have
participated in protocol DM 90 -063.
This study will determine the influence
of estrogen replacement on a patient’s
clinical course and the efficiency of
Premarin in the treatment of metabolic
bone disease.
Breast Cancer
Prevention Trial (BCPT)

Julie Jensen, RN, MSN, CANP, APNP
Coordinator
William Donegan, MD Principal Investigator
-

-

An important landmark against cancer
in 1998 was the report of the National
Breast Cancer Prevention Trial (BCPT)
which showed that the drug tamoxifen
could prevent 49% of breast cancers in
women at high risk for this disease. The
study involved 300 centers nationwide
and 13,388 volunteers who by reason of
their age or other risk factors were
considered at unusually high risk to
develop breast cancer.

The participants were assigned
randomly to take tamoxifen or an
inactive placebo orally each day for five
years. To eliminate any potential bias,
neither the participants nor the
physicians conducting the trial knew
which medication was assigned. The
study ran from April 1992 until the
spring of 1998, when the trial was
concluded and the results made known.
After less than four years on study,
women taking placebo had developed
175 invasive breast cancers while those
taking tamoxifen had developed only
89, a highly significant reduction. A
similar reduction in non-invasive breast
cancers was also seen.
An additional benefit of tamoxifen
therapy was the occurrence of fewer
bone fractures. The gains, however,
were at a price. Hot flashes were a
frequent side effect of tamoxifen, and
women over 50 years of age who took
it had a higher rate of endometrial
cancer, cataracts and potentially
dangerous blood clots in leg veins.
Women in the older age group with a
prior hysterectomy derived the greatest
net benefit.
The second national breast cancer
prevention trail, due to begin in January
of 1999, will compare tamoxifen with
raloxifene, a promising alternative that
may be even more effective and have
fewer side effects.
The BCPT was conducted by the
National Surgical Adjuvant Breast and
Bowel Project (NSABP) headquartered
in Pittsburgh, PA, and was funded by
the National Cancer Institute.

Sinai Samaritan Medical Center was the
coordinating site in Milwaukee for the
BCPT. Other Milwaukee participants
included St. Luke’s Medical Center and
Froedtert Hospital.
Vince Lombardi Cancer Clinic
In-House Research
Combination Immunotherapy
and Peripheral Blood Stem Cell
Transplantation (PBSCT) for
Women with Stage Ilib and
Metastatic Breast Cancer

Kristin Gleesing, RN, BSN Coordinator
Lawrence Lum, MD
Principal Investigator
-

-

The incidence of breast cancer among
US women is one in eight. Therapeutic
options for women with metastatic
breast cancer include high dose
chemotherapy with peripheral blood
stem cell transplantation. However,
even with PBSCT, the long-term cures
rates after PBSCT are poor with
recurrence rates of over 85%. Low cure
rates are likely due to tumor cells that
are reinfused in the PBSCT and/or
persist in the patient after doses of
chemotherapy. Since higher doses of
chemotherapy may lead to organ
dysfunction, non-toxic approaches are
needed to “mop up” breast cancer cells
that are reinfused or persist in the body.
For this reason, the Autologous Bone
Marrow Transplant (ABMI) program
at St. Luke’s Medical Center pioneered
a new cancer treatment protocol for
women with advanced breast cancer to
decrease relapse after PBSCT by using
adoptive immunotherapy to provide an
additional anti-tumor therapeutic
modality that is non-toxic to the
patient.
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The active clinical treatment protocol
included very high doses of chemo
therapy to maximize the killing breast
cancer cells prior to stem cell rescue;
PBSCT to rescue the patient’s bone
marrow function from high dose
chemotherapy; and immunotherapy
involving multiple infusions of the
patient’s own activated killer T cells and
interleukin 2 (an immune protein that
has anti-tumor activity) to accelerate
immune recovery and enhance antitumor effects. The T cells are triggered
to grow and kill by stimulation with
monoclonal antibody. The clinical trial
has both FDA and St. Luke’s Medical
Center Human Research Committee
approvals. This is the only clinical trial
using activated T cells, IL-2, and PBSCT
in the world for breast cancer.
The clinical trial has promising results
with 20 patients entered into the study.
The updated survival curves show that

St. Luke’s Medical Center
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75% of these patients are alive and 60%
remain free of recurrent disease at the
2$-month point in the study. In contrast,
only 50% of the women who received
PBSCT for metastatic breast cancer
without adoptive immunotherapy are
alive at the same time after PBSCT and
85% have relapse with breast cancer.
Although it is too early to form
conclusions, infusions of activated T cells
have gone smoothly without any major
side effects to the patients. There were no
deaths related to the transplant or cell
infusions. If the current trend continues,
the study may be able show that
adoptive immunotherapy with activated
T cells will provide a major benefit in the
treatment of breast cancer. ft is very
gratifying and encouraging that this nontoxic immunotherapy treatment
combination with PBSCT can be
provided as an alternative to women
with advanced breast cancer.

Radiation Therapy Oncology
Group Trials (RTOG)

NON-RELATED BREAST
CANCER PREVENTION TRIALS

Monique Swiecichowski, RN, BSN

Cancer and Leukemia Group B
(CALGB) Trials

Coordinator
Mitchell Pincus, MD Principal Investigator
-

Carol Tutino, RN, CCRC Coordinator
-

In 1997, the Radiation Therapy
Oncology Group (RTOG) offered four
J onathon Treisman, MD
new protocols in three disease sites to
Principal Investigators
St. Luke’s Medical Center radiation
patients:
therapy
In late 1997, St. Luke’s Medical Center
96-08 was designed to test the
RTOG
received permission to participate in the
results and toxicity of the addition of
CALGB Clinical Trials, which are
pelvic radiation to total androgen
sponsored by the National Cancer
suppression (TAS) in patients with
Institute for these studies. St. Luke’s is
lymph-node positive adenocarcinoma
affiliated with Mt. Sinai Hospital in New
of the prostate. All patients have their
York City. John P. Hanson, MD, is the
choice of Orchiectomy plus Flutamide
principal investigator at St. Luke’s.
or Casodex or a LHRH analog plus
Flutamide or Casodex. Randomization
Early in 1998, three CALGB protocols
determines the addition of whole
were reviewed and approved by the
pelvis irradiation.
St. Luke’s IRB for patient accural. These
RTOG 97-13 as previously mentioned,
three studies focus on GI malignancies.
made available to many women
was
They are:
with newly diagnosed breast cancer
Using a monoclonal antibody to treat
who had breast-conserving surgery
Stage II colon cancer (Modified
only, as prior treatment.
Astler-Coller B2). These patients
RTOG 97-14 compares a single
have undergone total resection of
fraction (8 Gy) to 10 fractions (30 Gy
their tumor. Typically these patients
total) for palliative treatment of
do not receive any type of therapy
prostate cancer (and breast) patients
after surgery.
with painful bone metastases.
Comparing different ways of giving
Frequency and duration of pain relief,
5FU for colon cancer patients who are
quality of life, cost-effectiveness, and
at high risk of recurrence, despite
incidence of secondary pathologic
surgical resection of the tumor. These
will be compared.
fractures
patients must be a Stage B2 with
is a Phase III
97-01
RTOG
obstruction or perforation, or be
of radiation alone
trial
randomized
a Stage Cl or C2.
chemotherapy
concurrent
versus
The third study will be comparing high
(Carboplatin and VP-16) plus
dose vs. conventional dose octreotide
therapy for poor-risk
radiation
acetate vs. loperamide in the treatment
ll lung carcinoma
non-small-ce
III
Stage
of chemotherapy induced diarrhea in
evaluate
will
study
This
patients.
patients with colorectal cancer.
whether the survival rate is improved,
quality of life affected, and treatmentrelated morbidity is increased by
adding con-current chemotherapy to
radiation therapy.
John P. Hanson, MD and

-

—

—

—

—

•

••

-

—

—

—
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The RTOG continues to explore the use of
“new modality” treatment in varying
disease sites. Brachytherapy, stereotactic
radiosurgery, and dose escalation using 3D
conformal radiation therapy are currently
being explored for use in breast, brain,
prostate and lung cancers. Specifically, we
eagerly await the activation of an RTOG
prostate protocol utilizing radioactive seed
implants a procedure we have quite a bit
of experience in and a huge patient
demand for. RTOG 9805 will be made
available to patients as soon as the RTOG
implant credentialing is completed.

VINCE LOMBARDI
CANCER CLINIC
IN-HOUSE PROTOCOLS
The Vince Lombardi Cancer Clinic at
St. Luke’s Medical Center is continuing to
accrue patients in a number of in-house
clinical research studies.

—

Antiemetic (Anti-nausea) Protocol Study
for Patients Undergoing Autologous
Bone Marrow Transplant

Kristine Gleesing, RN, BSN Coordinator
Sol Yoder, PharmD
Robert Taylor, MD Principal Investigator
-

Eastern Cooperative Oncology
Group Trials (ECOG)

-

The hypothesis in this study is that
antiemetic protocol utilizing an algorithm
of nausea and vomiting associated with
high-dose chemotherapy in bone marrow
transplantation is more cost effective than
the method in which antiemetics are
currently prescribed by the physician.

Nancy Briggs, RN, MSN, OCN Coordinator
Gary Shapiro, MD Principal Investigator
-

-

Sinai Samaritan Medical Center is an
affiliate of the University of Wisconsin’s
Comprehensive Cancer Center. In con
junction with the Eastern Cooperative
Oncology Group (ECOG) more than 60
clinical trials are available to patients,
addressing a wide variety of cancers and
symptom management. In conjunction
with the Eastern Cooperative Oncology
Group (ECOG), research studies in breast,
lung, colon and prostate cancer have
continued to generate the highest numbers
of patient accrual. Enrollment of women
and minorities has continued to be an area
of strength for the research program.

Value of Flexible Sigmoidoscopic
Screenings in Detecting Colorectal Cancer
In Younger Adults

Carol Tutino, RN, CCRC Coordinator
Daniel Geenen, MD Principal Investigator
-

-

The study offers free flexible sigmoido
scopic examinations for eligible 35-50 year
olds and hopes to answer the following
questions: What is the incidence of polyp
detection in three non-identified high risk
asymptomatic age groups? What are the
characteristics of polyps removed from
each age group? What is the incidence of
specific risk factors for colon cancer in
each of these age groups? And, how does
the incidence of these risk factors differ
between patient who have polyps vs. those
who do not?

Through its relationship with the
University of Wisconsin Comprehensive
Cancer Center (UWCCC), Sinai Samaritan
Medical Center is a charter member of the
Wisconsin Oncology Network (WON).
This new statewide network of UWCCC
affiliated hospitals and clinics will provide
Wisconsin’s cancer patients greater
accessibility to innovative investigational
cancer treatments.
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Women Supporting Women
Women Supporting Women is a group
of African American women who have
survived cancer. Their mission is to be
concerned and committed to providing
education, support and enhancement to
women of color challenged by breast
cancer. Jestene McCord, Director of
Urban Affairs, is the facilitator and
can be reached at 647-3344 for more
information.
Meets the third Saturday of each
month at the House of Peace,
17th and Walnut, from 11:00 a.m.
to 12:30 p.m.

feast Cancer
Support Groups

C

—

Education, inspiration and a sharing
of experiences for people whose lives
have been touched by cancer

Jewish Community Center (ICC)
Breast Cancer Support Group
The JCC breast cancer support group is
offered by the Jewish Community Center
and Sinai Samaritan Medical Center and
is open to all interested women.
For information contact Oza Mae
Homes, RN, BSN, OCN at 219-7360.
Meets every other Thursday from
10:00 a.m. to 12:00 p.m. Sessions run
from September through May.

The following support groups offer
women the opportunity to share
experiences, grieve and celebrate while
maintaining their privacy. The groups
offer education as well as support.
Expert speakers on various topics are
brought in to have discussions with the
members. Topics include chemotherapy,
lymphedema, music therapy, spirituality,
meditation/visualization, nutrition
and alternative therapies. The
members of the groups determine
what topics they are most interested
in learning about.

—

Breast Friends
Breast Cancer Support Group
Breast Friends is for women who have
been diagnosed with breast cancer,
their families and friends. Sessions
are facilitated by the coordinator of
St. Luke’s comprehensive breast care
program, and are open to all women
with breast cancer and their husbands,
sisters, friends, daughters and others.
Meets the last Tuesday of each month
from 6:00 to 8:00 p.m. in the
Vince Lombardi Cancer Clinic at
St. Luke’s Medical Center.
-

—
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ther
Cancer Support Groups

Positive People
For people with cancer, their families
and friends. By sharing experiences,
gaining insight and information,
participants strive to find a new and
positive attitude.
Meets the second Wednesday of each
month from 7:00 to 8:30 p.m. at
West Allis Memorial Hospital.
For more information, call 322-6220.

The following support groups were
organized specifically to support people
with cancer and their families and
friends. There is no charge for attending
these groups. Patients and families are
encouraged to attend as many sessions
as they wish.

C

—

For more information about cancer
support groups within the Metro Region
of Aurora Health Care, please call the
Vince Lombardi Cancer Hotline at
649-7200 in Milwaukee or
1-800-252-2990 outside Milwaukee.

US TOO
Prostate Cancer Support Group
For men who have experienced prostate
cancer, their families and friends. Sessions
are facilitated by a clinical nurse
specialist, chaplain, physician and/or
other health care professionals.
Meets the first Thursday of each
month from 1:00 to 2:30 p.m. or
7:00 to 8:30 p.m. at St. Luke’s
Medical Center
Meets the first Wednesday of each
month from 7:00 to 2:30 p.m. at
St. Luke’s New Berlin Health Care
Cente;; 14555 West National Avenue.
Meets the first Wednesday of each
month from 10:00 to 11:30 a.m. at
Aurora Medical Group Northsh ore,
2706 North Port Washington Road.

—

Your Caring Connection
For people who have experienced cancer,
their families and friends. Topics of
discussion focus on many aspects of
cancer education, with presentations
given by St. Luke’s Medical Center
doctors, nurses, social workers,
psychologists, chaplains, and other
health care professionals.
Meets the second and fourth Monday
of each month from 6:30 to 8 p.m. in
the Radiation Oncology Conference
Room at St. Luke’s Medical Center.
Registration is not required.

—

—

—

Ovarian Cancer Awareness Group
For women who are at risk for or who
have been diagnosed with ovarian cancer.
Health care professionals offer educa
tional information on risk factors and the
latest treatment options, and provide an
opportunity for communication and
emotional support.
Meets the first Tuesday of each month
from 6:30 to 2:00 p.m. in the Vince
Lombardi Cancer Clinic at St. Luke’s
Medical Center.

Make Today Count
For people with cancer or other lifethreatening illnesses. Co-sponsored by
St. Luke’s and the American Cancer
Society, the group helps improve the
quality of life for people with serious
illness through positive support and
open communication.
Meets the fourth Thursday of each
month from 7:00 to 8:30 p.m. at
St. Luke’s South Shore, 5900 South
Lake Drive.

—

—
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The Kid’s Connection
For children ages 5 through 18 whose
parent or loved one has cancer. Partici
pation helps children learn about cancer,
express their feelings and discuss their
experiences with other children. Sessions
are facilitated by St. Luke’s child life and
cancer nursing specialists.
Meets for four weekly sessions at
St. Luke’s Medical Cente; Registration
is required. For more information, call
the Vince Lombardi Cancer Hotline at
649-7200 or 1-200-252-2990.
—

The ABMT Support Group
For people who have undergone an
autologous bone marrow transplant
(ABMT). Facilitated by members of
St. Luke’s ABMT team, the group offers
support and educational information in
a nurturing environment.
Meets in the Vince Lombardi Cancer
Clinic at St. Luke’s Medical Cente,:
For information on dates and times,
call the Vince Lombardi Cancer
Hotline at 649-7200 or
1 -200-252-2990.
—

Look Good. Feel Better
For people who are undergoing cancer
treatment. This program presents
techniques to help people gain control
and even triumph over the cosmetic side
effects of treatment. Topics of discussion
and demonstration include hair styling,
wigs, scarves, nails, skin care and
make-up. This program is sponsored by
St. Luke’s Medical Center and the
American Cancer Society in affiliation
with experts from the cosmetics industry.
Meets six Mondays per year from
1:00 to 4:00 p.m. Call 649-7200 or
1-800-252-2990 for specific dates
and locations.
.

.

—

Refocusing on Hope
For people with primary brain tumors.
Sessions are facilitated by nurses who
work directly with people who have
brain tumors.
Meets the second Wednesday of each
month from 7:00 to 2:30 p.m. in the
Radiation Oncology area at St. Luke’s
Medical Center.
—
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pedal Events

Samaritan Medical Center participated in
a panel discussion at Grand Avenue Mall
about new treatment options for breast
cancer.

Aurora Health Care was involved in
several special events in 1997 to help
raise awareness of certain types of
cancer and to educate individuals
about their risk and the importance
of early detection.

In recognition of Breast Cancer Awareness
Month in October, Aurora Health Care
and WTMJ-W formed a community
partnership to promote breast health to
women in the Channel 4 viewing area.
Throughout the month, promotional spots
and news stories highlighted patients and
promoted breast care. Breast health experts
manned a telephone bank to answer callers’
questions and take requests for a free breast
health kit from Aurora Health Care. The
kit included information on breast self
exam, the location of Aurora mammo
graphy sites in southeastern Wisconsin and
a coupon for a discounted mammogram.

Two special events were held at Sinai
Samaritan Medical Center in April. The
Breast Self Examination Group met
April $ to hold Breast Health Facilitator
Training and on April 30, Oncology
Nursing Day was celebrated by having
nurses familiarize themselves with all
aspects of outpatient and inpatient
oncology care through participation in
a “treasure hunt.”
On May 4, an 8$-member team, comprised
of staff, patients, family and friends walked
in the Strides Against Breast Cancer, a fivemile walk along the lakefront sponsored by
the American Cancer Society. The Aurora
team raised $2,710 in support of breast
cancer research.

-Il

.
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In November the hospitals in the Aurora
Metro Region endorsed the Great American
Smoke Out by displaying posters and flyers
encouraging patients to quit smoking. The
project was in conjunction with the NICO
Free Teens Project in which St. Luke’s
Medical Center partnered with the
American Cancer Society, the West Allis
Health Department and Nathan Hale High
School in creating a youth smoking
cessation pilot program during the
Fall 1997. This was a peer led program
mentored by the Cancer Services staff from
St. Luke’s Medical Center.

p

In June, St. Luke’s Breast Care Program
organized the local portion of the
BMW Drive For The Cure, an event
designed to increase awareness for early
detection of breast cancer as well as to raise
money to further the mission of the Susan
G. Komen Foundation, a national
organization for breast cancer research and
awareness. Two caravans of speciallymarked BMW vehicles simultaneously
drove across the United States, stopping in
more than 90 cities where local dealerships
hosted special activities. Each leg of the
journey required volunteer drivers for the
cars. BMW donated one dollar for each
mile driven in each car during the tour and
in test drives. The national goal of one
million miles/dollars was surpassed.

I

Marie Reuter had an autologous bone
marrow transplant for the treatment of
breast cancer on July 23, 1996. On June 7,
1998, she and her daughter attended Cancer
Survivors’ Day, an annual community-wide
celebration sponsored by Aurora Health
Care and the American Cancer Society.

June also brought The Faces Of Breast
Cancer to Milwaukee, a traveling exhibit
of photos of women from all 50 states
who have died of the disease. During the
exhibition, health professionals representing
St. Luke’s Medical Center and Sinai
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ancer Conferences in the
Aurora Metro Region
Tumor Board cancer conferences are
held weekly at St. Luke’s Medical Center,
Sinai Samaritan Medical Center and
West Allis Memorial Hospital and twice
each month at Hartford Memorial
Hospital. These oncology-specific
conferences represent a team approach to
care for Aurora Health Care cancer
patients, as well as being an educational
tool for the entire spectrum of health care
providers. Pathology slides and pertinent
radiology films are reviewed, and
opinions on treatment options are
rendered by specialists from medical
oncology, radiation oncology, surgery and
other disciplines. This enables the
managing physicians to better advise
patients of their treatment choices and

CD
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allows patients to make informed
decisions regarding their care. Each
facility presents at least 10 percent of its
analytic caseload with an average of
three cases presented each week. The
majority of the discussion focuses
on prospective cancer cases with a
limited number of didactic lectures for
educational purposes of new treatment
approaches and techniques. Video
conferencing capability is being
experimented with for broadcasting
didactic type lectures across the region.
As referred to previously in this report,
Breast Cancer Conferences are another
prospective multidisciplinary conference
held on a regular basis at St. Luke’s
Medical Center and Sinai Samaritan
Medical Center.

AURORA METRO REGION CANCER CONFERENCES
Sinai Samaritan Medical Center’s
Breast Conference is dedicated to the
fourth Friday of the month.

St. Luke’s Medical Center holds Tumor
Board Conferences on Mondays at
12:00 p.m. in HS3.
—

I...’

St. Luke’s Medical Center holds Breast
Conferences on the first and third
Wednesdays of the month at 7:30 a.m.
in H53.

—

—

St. Luke’s Medical Center dedicates the
third Monday of each month to Head
and Neck Tumor Conferences.
—

Sinai Samaritan Medical Center’s
Tumor Board Conferences are on
Fridays at 12:00 p.m. in Rapkin
Auditorium.

—

West Allis Memorial Hospital holds
conferences on Fridays at 12:00 p.m.
in conference room A/B.
Hartford Memorial Hospital holds
conferences during the fourth week of
each month. Contact the Department
of Pathology for dates and times.
St. Luke’s South Shore holds
conferences every other month.
Contact the clinical data registry for
dates and times.

Each facility is accredited by the State Medical Society of Wisconsin to sponsor
continuing medical education for physicians and designates these continuing medical
education programs for 1 credit hour in category 1 of the physician’s recognition award
of the American Medical Association.
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egional Cancer
Registry Report
Lisa Robinson, RRA, CTR

The Cancer Programs at Sinai Samaritan
Medical Center, St. Luke’s Medical Center and
West Allis Memorial Hospital are all approved
cancer programs and follow the guidelines set
forth by the American College of Surgeons
“Commission on Cancer.” The Aurora Health
Care Metro Region is well on its way to
accomplishing the goal of becoming one of the
first networked-approved cancer programs in
the country. In striving toward that goal, each
of our cancer programs has been, or is expected
to receive, full four-year approval, the highest
award a cancer program can receive. By
achieving excellence first as individual
institutions, we can then lead the way for being
the best health care provider network of cancer
programs in the country.

In 1997, regionalization plans were underway to
promote unity among the Aurora Health Care
facilities in Southeastern Wisconsin. One of the
regional plans for the Clinical Information
Services (CIS) Department, headed by Catherine
Ptak, RRA, Director, was to unify the registries
at St. Luke’s Medical Center, Sinai Samaritan
Medical Center and West Allis Memorial Hospital.
The tumor registry of the past would take on
new responsibilities and a new name. The
cancer registrars at each facility are now called
“Clinical Data Registrars.” Still highly skilled at
collecting cancer data, the registrars also collect
cardiac, perinatal, protocol and outcome data.
Between the three facilities, Aurora Health Care
employs seven certified tumor registrars (CTRs),
with others credentialed as Registered Record
Administrators (RRA) or Accredited Record
Technicians (ART). To maintain a high level of
knowledge, employees are required to attend a
variety of continuing educational activities on a
yearly basis, including weekly tumor board
meetings, the National Cancer Registrars
Association (NCRA) Meetings, the Wisconsin
Cancer Registrars Association (WCRA)
Meetings, the Southeastern Wisconsin Cancer
Conference (SEWCC), and the Annual
Commission on Cancer (COC) meeting
held in Chicago.

As with any approved cancer program, the
cancer registries of our hospitals are essential in
bringing together all the pieces of the cancer
program. Registrars are responsible for the
components listed below, which ultimately
reflect the care our facilities provide to patients.
The registries in the Metro Region of Aurora
Health Care take pride in providing timely,
consistent and quality data to our customers.
The following statistical data are provided by
each of our hospitals. If you would like more
information on how the clinical data registries
can provide data, please call (414) 649-7290.

REGISTRARS
—

—

—

—

Casefind and abstract cancer patient demo
graphics, workup, treatment and outcome.
Provide survival statistics by conducting
annual surveillance of accessioned cancer
patients.
Plan, organize and promote educational
multidisciplinary cancer conferences.

—

—

—

Participate in hospital and ACOS
recommended quality improvement studies.
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—

Submit required data to the State and the
National Cancer Data Bases (NCDB).
Respond to requests for information,
and distribute yearly statistics for
administrative planning.
Initiate and evaluate the quality control
review of 10% of the abstracted analytical cases.
Actively participate in cancer committee and
cancer care service meetings.

C

Statistical Summary Review of 1997 Data

cc

January 1, 1985 is the reference year for which the cancer registries at St. Luke’s
Medical Center (SLMC) and Sinai Samaritan Medical Center (SSMC) have been actively
accessioning and following cancer cases. West Allis Memorial Hospital’s (WAMH)
reference date is 197$. The number of new cancer cases continues to increase at
St. Luke’s Medical Center (1,868) while the number of cases at Sinai Samaritan Medical
Center (316) and West Allis Memorial Hospital (464) has decreased. This change in
distribution coincided with changes in contracts with managed care providers and
regionalization of services throughout the Metro Region of Aurora Health Care.

Accession Year Distribution by Facility
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TOTAL
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SLMC

1886

1576

310

SSMC

316

291

25

WAMH

464

431

33

2666

2298

368
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1996
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Total

1
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WAMH

The Cancer Registries in the
approved cancer programs of
the Metro Region of Aurora
Health Care accessioned a
total of 2,666 new cancer
cases in 1997. Of these cases,
2,298 were analytical (newly
diagnosed and/or treated at a
Metro facility) and 368 cases
were non-analytical (previously
diagnosed and/or treated
elsewhere). Currently, cases are
entered into separate databases
at each hospital. Future plans
include integrating the
disparate systems into one
multi-hospital networked
software for all sites.

.

Comparison of Top Five Sites
25%
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Breast

Colorectal

— —
Prostate

Lung

Bladder

Top 5 Sites
• Metro %

State %

US %

This figure compares the top five cancer sites at each facility. All hospitals
had the same common sites with the exception of Sinai Samaritan Medical
Center, where cervix surpassed bladder in part due to the Women’s Health
Center. Each site was comparable to the state and national statistics with
the exception of prostate. National statistics reflect the increased incidence
of prostate cancer being diagnosed and treated outside of hospitals.

SLMC

SSMC

WAMH

Breast

296

90

78

464

Prostate

260

17

58

335

Lung

240

33

65

338

Colorectal

208

45

72

325

Bladder

92

5

32

129

Cervix

24

12

6
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Top 5 Sites by General Summary Stage
Aurora Metro Region Hospitals 1997
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SEER General Summary Stage

• prostate
• bladder

• breast
• colorectal

• lung

A grouped comparison of diagnosis according to general summary stage is
graphed by site above for a combined look at the Metro Region. Bladder, breast
and prostate are three sites that are diagnosed at a relatively early stage of
disease, whereas lung and colorectal had a higher percentage of patients that
were diagnosed during a later stage of disease.
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Top 5 Sites by General Summary Stage
Wisconsin Cancer Incidence & Mortality
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The hospitals in the Metro Region of Aurora Health Care compare favorably to
the incidence by stage from the state statistics. Bladder, breast and prostate
cancer cases are diagnosed at an earlier stage than lung and colorectal cancers.
Aurora’s colorectat cases are diagnosed at an earlier stage than is the trend at
the state level.
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Race Distribution
Aurora Metro Region Hospitals 1997
White

AfricanAmerican

Native
American

Asian

Other

SLMC

97%

2%

.25%

.25%

.5%

SSMC

40%

56%

.6%

1.2%

2.2%

WAMH

99%

05%

0

.05%

0

Ethnicity of the 2,666 cases accrued in 1997 is shown in Table 1. The
population served at SLMC and WAMH is predominately white. By contrast,
the central city location of SSMC serves a more diverse multicultural population.

E
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Gender 1997 by Facility
1000
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WAMH
Males
Females
Of the newly diagnosed cancer cases, distribution by age and sex shows that a cancer
diagnosis is most frequently found in those between the ages of 60-69 for men, and
70-79 for women. The increased frequency of women developing cancer under the
age of SO is reflective of the screenings for women’s malignancies at an earlier age
than men, i.e. mammograms and pap smears.
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5-Year Survival Metro Region
I
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Follow-up Percentages 1997
-

p.

WAMH
92%

SLMC
94%

SSMC
92%

Follow-up is maintained on all patients in the registries excluding basal and squamous
cell carcinomas of the skin (TO-Ti), carcinoma in situs of the cervix and foreign
residents. Lifetime follow-up provides a continuous prospective of the results of
treatment and survival outcome, as well as serving as a reminder to physicians and
patients about the importance of yearly follow-up. The follow-up success rate is
maintained above the ACoS standard at all of our facilities on a regular basis.

52

1997

SITE DISTRIBUTION FOR
BREAST

SLMC

SSMC

WAMH

TOTAL

78

464

296

90

LUNG

240

33

65

338

PROSTATE

260

17

58

COLORECTAL

20$

45

72

335
325

BLADDER/URETER

92

5

32

129

LYMPHOMA

62

7

23

92

HEMATOPOIETIC

60

11

14

85

KIDNEY/RENAL PELVIS
SKIN:

66

5

9

80

52

2

69

ENDOMETRIUM

39

9
11

20

70

UNKNOWN PRIMARY
LIPORAL CAVITY

45

10

5

60

37

5

8

50

PANCREAS

28

48

24

$
12

12

CERVIX
ESOPHAGUS

30

STOMACH
OVARY & UNSPEC. SITES
BRAIN, CNS, NERVES
LARYNX
LIVER

14

THYROID/ENDOCRINE
TESTIS
SOFT TISSUE
GALL BLADDER, BILE DUCTS
VAGINA/VULVA

6

42

5

41

22

6
11

8

41

32

5

3

40

27

4

5

36

26

2

8

36

3

22

12

5
1

7

20

15

0

2

17

15

1

0

16

10

3

16

SMALL INTESTINE

6
4

3
2

3
2
5

11

THYMUS, HEART, MEDIASTINTJM,
PLEURA

8

1

1

10

BONE

8

1

0

9
$

11

EYE/ADNEXA

7

1

0

RETROPERITONEUM, PERITONEUM
NASAL CAVITY/ACCESSORY SINUSES
ANUS

6

1

0

7

3

1

4

4

0
2

0

BASAL AND TI SCC OF SKIN

158

0

0

6
158

TOTALS

1886

316

464

2666

*Excludes Basal and TI SCC of skin
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urora Health Care Metro Region
Cancer Services Directory
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ST. LUKE’S MEDICAL CENTER
Departments & Clinics

Support Services

$ GHJK (Inpatient Unit)
(414) 649-6477

Clinical Nurse Specialist
(Vince Lombardi Cancer Clinic)
(414) 649-7561

Radiation Therapy
(414) 649-6420
•

C)

Vince Lombardi Cancer Clinic
St. Luke’s Medical Center
(414) 649-6380
Vince Lombardi Cancer Clinic-Slinger
(414) 644-2960

U
C)

Women’s Health Unit
(414) 649-6521

Communicare Express Van
(Transportation)
(414) 649-6123
Dietitian (Nutritional Services)
(414) 649-7672
Outpatient Cancer Services Pharmacist
(414) 649-6468
Pastoral Care Office
(414 649-6072

Treatment Programs

Autologous Bone Marrow
Transplant Program
(414) 649-6540

r1+L

Social Work & Continuing Care
(414) 649-6340
Support Group Information
(414) 649-7200

Breast Care Program Coordinator
(414) 649-7605

Education/Resources

GYN Cancer Surgical Services
(414) 649-6380

Financial Counseling
(414) 649-7093

Head and Neck Cancer Services
Coordinator
(414) 649-7823

Clinical Data Registry
(414) 649-7290

Immunotherapy/Gene Therapy Program
(414) 649-7823

Medical Library
(414) 649-7356

Musculoskeletal Cancer Program
Coordinator
(414) 649-6178

I

Neurosurgical Services
1-888-50-Brain
Radiation Therapy
(414) 649-6420
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WEST ALLIS MEMORIAL HOSPITAL

Outpatient Oncology
(414) 489-4051

Departments
4 South (Inpatient Unit)
(414) 328-6545

•

SnA1 SAMARITAN MEDICAL CENTER

Departments and Clinics

Medical Oncololgy Clinic
(414) 328-8850

4 South (Inpatient Unit)
(414) 219-6599

Radiation Therapy
(414) 328-6460

Medical Oncology Clinic
(414) 219-7370

Treatment Programs

•

C.?

Breast Care Program Coordinator
Nancy Rhodes
(414) 328-7407

Radiation Therapy
(414) 219-7140
Women’s Care Center
(414) 219-5727

Support Services

Treatment Programs

Clinical Nurse Specialist
(414) 328-6281

Breast Health Center
(414) 219-7360

Freedom 55/65
(414) 328-7410

Support Services

Pastoral Care Department
(414) 328-6845

Clinical Nurse Specialist
(414) 219-7321

Social Services
(414) 328-6188

Freedom 55/65 Courtesy Van Services
(Transportation)
(414) 219-5444

West Allis Memorial Hospital Van
Service (Transportation)
(414) 328-7433

Pastoral Care Department
(414) 219-6080

Education/Resources

Social Services
(414) 219-7562

Clinical Data Registry
(414) 328-7122

Education/Resources

Medical Library
(414) 328-7910

Clinical Data Registry
(414) 219-6039
Medical Library
(414) 219-6710
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ancer Committee Mem ers ip 1997
By Aurora Metro Region Hospitals
St. Luke’s Medical Center
Marcia Richards, MD Chairman, Radiation Oncology
Marc Catalano, MD Gastroenterotogy
Aiteen Denny, MD Medical Oncology
Jeffrey Derus, MD Urology
William Deshur, MD Surgery
A/it Divgi, MD Medical Oncology
John Hanson, MD Medical Oncology
Ronald Hart, MD Medical Oncology
Elmer Lehman, MD Gynecologic Oncology
Howard Lewis Radiation Oncology
Mahmood Mirhoseini, MD Cardiothoracic Surgery
Gordon Mortensen, MD Ansthesiology
David Munoz, MD Family Practice
Michael Nordstrom, MD Otolaryngology
William Pao, MD Radiation Oncology
Jorge Pellegrini, MD Pathology
Nancy Petro, MD Surgery
Elaine Thomas, MD Pediatrics
Jonathon Treisman, MD Medical Oncology
Mark Wenzel, MD Radiology
Vicky George, RN Administration
Patty Abella, RN Oncology Nursing
Man/a Bjegovich Weidman, RN Cancer Services
Sandy Blixt, RRA Cancer Registry
Mary Fields Business and Market Development
Sheri Hackbarth, RRA Cancer Registry
Elizabeth Hansen, RN Research
Kristine Hegmann Quality Management
Vicky Koceja RN, OCN Inpatient Nursing
Pam Lyon, RN, OCN ABMT Program
Marica Marino Pastoral Care
Grace Jessen, CICSW Social Work
JoAnn Paulson, RN Visiting Nurse Association
Mary Schmidt, RN, MS. AOCN CNS 8GHJK
Ellen Toth Information Systems
Kerry Twite, RN, OCN- CNS Vince Lombardi Cancer Clinic
Phil Whitton, RTT Manager Radiation Oncology
Sot Yodei; PharmD Pharmacy
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Sinai Samaritan Medical Center
William Donegan, MD Chairman, Surgery
Betty Amuzu, MD OB/GYN
Reuben Elsenstein, MD Pathology
Howard Johnson, MD Radiology
Thomas Kinney, MD Plastic Surgery
Scott Levin, DDS Oral Surgery
Mitchell Pincus, MD Radiation Oncology
Gary Shapiro, MD Medical Oncology
Marjorie Strack, MD Medical Oncology
Len Wilk, FA CHE Administration
Marija Bjecgovich Weidman, RN Cancer Services
Nancy Briggs, RN, OCN Research
Oza Holmes, RN OCN Breast Health Center
Julie Jensen, RN, OCN Nursing
Janet Lotegeluaki, RN, OCN CNS
Pam Maier, RN Inpatient Nursing
Mary Mavraganis, MSW Social Services
Lisa Robinson, RRA, CTR Cancer Registry
Joan Sagan, RN, OCN Medical Oncology
Peg Schmidt, RRA Clinical Information Services
Judy Ziltman, RN Quality Management
-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

West Allis Memorial Hospital
Maury Berger, MD Chairman, Medical Oncology
Linda Barrows, MD Physical Medicine & Rehab
Kenneth Bastin, MD Radiation Oncology
James Dolan, MD OB/GYN
Donald Feinsilver, MD Psychiatry
John Hanson, Ji:, MD Medical Oncology
Ronald Hart, MD Medical Oncology
Rakesh Jagetia, MD Radiation Oncology
John Kelly, MD Otolaryngology
Thoms Lass, MD Anesthesiology
Samuel Otto, MD Urology
Terrance Roth, MD Surgery
Steven Sperling, MD Radiology
Rodolfo Suaverdez, MD family Practice
Shelly Underhill, MD Pathology
Rick Kellar Administration
Marija Bjegovich Weidman, RN Cancer Services
Priscilla Eckert, ART, CTR Cancer Registry
Pat Kadiec, RN OPD Nursing
Dale Miller, RPH Pharmacy
Becky Pogacar, MSN Inpatient Oncology
Blanch Schearer, RN Oncology Nursing
Vicky Shackley, RN Quality Management
Patricia Stoll, MSW Social Services
Phil Whitton Radiation Oncology
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St. Luke’s Medical Center
Sinai Samaritan Medical Center
West Allis Memorial Hospital
AuroraHea1thCare

Aurora Health Care
2900 West Oklahoma Ave.
Milwaukee, WI 53215
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